Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 phase 2 trial

*[1]Francesco Perrone, *[1]Maria Carmela Piccirillo, [2]Paolo Antonio Ascierto, [3]Carlo Salvarani, [4]Roberto Parrella, [5]Anna Maria Marata, [6]Patrizia Popoli, [7]Laurenzia Ferraris, [7]Massimiliano M. Marrocco-Trischitta, [8]Diego Ripamonti, [8]Francesca Binda, [9]Paolo Bonfanti, [9]Nicola Squillace, [10]Francesco Castelli, [10]Maria Lorenza Muiesan, [11]Miriam Lichtner, [12]Carlo Calzetti, [13]Nicola Duccio Salerno, [4]Luigi Atripaldi, [14]Marco Cascella, [15]Massimo Costantini, [3]Giovanni Dolci, [15]Nicola Cosimo Facciolongo, [4]Fiorentino Fraganza, [15]Marco Massari, [4]Vincenzo Montesarchio, [16]Cristina Mussini, [15]Emanuele Alberto Negri, [1]Gerardo Botti MD, [1]Claudia Cardone, [1]Piera Gargiulo, [1]Adriano Gravina, [1]Clorinda Schettino, [1]Laura Arenare, °[17]Paolo Chiodini, °[17]Ciro Gallo, on behalf of the TOCIVID-19 investigators (see Appendix for a complete list), Italy

* contributed equally, ° contributed equally

[1] Clinical Trial Unit, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli, [2] Melanoma. Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli, [3] Università degli Studi di Modena e Reggio Emilia and Azienda USL-IRCCS di Reggio Emilia, [4] Cotugno Hospital, AORN Ospedali dei Colli, Napoli, [5] Emilia Romagna Health Directorate, Bologna, [6] Center for Drug Research and Evaluation, Istituto Superiore di Sanità, Roma, [7] Infectious Diseases Unit, Hospital Health Direction, IRCCS - Policlinico San Donato, Milano, [8] Infectious Diseases Unit - ASST Papa Giovanni XXIII, Bergamo, [9] Infectious Diseases Unit, ASST Monza and University Milano Bicocca, [10] University of Brescia and ASST Spedali Civili, Brescia, [11] Sapienza University of Rome, Santa Maria Goretti Hospital, Latina, [12] Infectious Diseases and Hepatology Unit AOU Parma, [13] UOC Malattie Infettive e Tropicali, AOUI, Verona, [14] Anesthesia and Resuscitation Unit, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli, [15] Azienda USL-IRCCS di Reggio Emilia, [16] Università degli Studi di Modena e Reggio Emilia, [17]Department of Mental Health and Preventive Medicine, Università degli Studi della Campania Luigi Vanvitelli

Corresponding author:

Francesco Perrone
Clinical Trial Unit
Istituto Nazionale Tumori di Napoli
f.perrone@istitutotumori.na.it
fax +390817702938

Abstract

Background: Tocilizumab blocks pro-inflammatory activity of interleukin-6 (IL-6) which might be important in the pathogenesis of interstitial pneumonia.

Objective: to evaluate efficacy of tocilizumab in COVID-19 pneumonia patients.

Design: multicenter single-arm phase 2 trial, powered to detect 10% absolute lethality rate reduction at 14 and 30-days, with 20% and 35% expected rates. A consecutive prospective validation cohort was also evaluated.

Setting: 185 Italian public hospitals, during coronavirus breakout.

Patients: 1221 patients hospitalized with pneumonia, from March 19th to 24th, 2020.

Intervention: tocilizumab 8 mg/kg, intravenously, one or two administrations with 12 hours interval.

Measurements: lethality rates at 14 and 30-days; safety according to CTCAE.

Results: 301 and 920 cases were available for intention-to-treat (ITT) analysis in phase 2 and validation cohorts. Due to delayed drug availability, 60% of patients received tocilizumab, and with some delays. In phase 2, 67 patients died; lethality rates were 18.4% (97.5%CI: 13.6-24.0, P=0.52) and 22.4% (97.5%CI: 17.2-28.3, P<0.001) at 14 and 30-days. Lower rates (15.6% and 20.0%) were reported in the modified ITT including only treated patients (mITT). Lethality rates in the validation cohort were smaller than in phase 2, at 14 and 30 days and in ITT and mITT populations. Multivariable logistic regression model suggests tocilizumab be more effective in patients not requiring mechanical respiratory support at baseline. No relevant signal of specific drug toxicity was reported, many severe adverse events being disease-related.

Limitations: single-arm design. In addition, delayed availability of the drug induced indication bias and immortal time bias.

Conclusion: Tocilizumab reduced lethality rate at 30 but not at 14-days, compared with the expectations, without significant toxicity. Efficacy was more evident among patients not requiring mechanical respiratory support.

Registration. EudraCT (2020-001110-38); clinicaltrials.gov (NCT04317092)

Funding. No specific funding was available for the study. Tocilizumab was provided by Roche free of charge.

Introduction

Pneumonia is the most frequent and serious complication of COVID-19, due to excessive host immune response causing an acute respiratory distress syndrome.(1-5)

Interleukin 6 (IL-6) is a pro-inflammatory cytokine implicated in several rheumatic diseases and in the so-called cytokine release syndrome (CRS). Tocilizumab is a recombinant humanized monoclonal antibody, directed against the IL-6 receptor. It is indicated for treating severe rheumatoid arthritis, systemic juvenile idiopathic polyarthritis and severe cytokine release syndrome (CRS) induced by chimeric antigen receptor T-cells (CAR-T).(6, 7)

Chinese researchers treated 21 patients with severe or critical COVID-19 pneumonia with tocilizumab 400 mg iv with efficacy in terms of reduction of oxygen requirement (15/20), resolution of radiologic lung lesions (19/21), normalization of lymphocyte count (10/19), and reduction of C-reactive protein levels (16/19).(8) These results prompted a randomized trial (tocilizumab vs control, ChiCTR2000029765) including 188 patients, expected to reach the planned accrual by mid-May 2020.

Therefore, to describe efficacy of tocilizumab while controlling the highly increasing off-label use of the drug, we launched the TOCIVID-19 study, on March 19th, 2020 during the ascending phase of the Italian breakout.

Methods

According to a specific Italian law, TOCIVID-19 was approved for all Italian centers by the National Ethical Committee at the Lazzaro Spallanzani Institute on March 18th, 2020; two amendments followed on March 24th, 2020 and April 28th, 2020. Database was frozen on May 4th, 2020.(9)

Study design

TOCIVID-19 is an academic, no-profit, multicenter, open-label trial including a single-arm phase 2 study, and a companion cohort study.

Sample size for the phase 2 study was initially calculated using 1-month lethality rate as the primary endpoint; based on March 10th daily report on Italian breakout, 1-month mortality for the eligible population was estimated around 15%; 330 patients were planned to test the alternative hypothesis that tocilizumab may halve lethality rate (from 15% to 7.5%), with 99% power and 5% bilateral alpha error.

The March 28th amendment, increased the number of patients to be registered to 400, to contrast possible ineligibility after registration, and introduced the companion cohort study of subjects eligible for phase 2 but exceeding the planned sample size, prospectively

registered between March 20th and March 24th, 2020, to possibly corroborate phase 2 findings.

The April 28th amendment introduced 14-days lethality rate as co-primary endpoint and redefined the expected lethality rates (null-hypotheses) at 14 and 30-days at 20% and 35%, respectively, thanks to data received from the Italian National Institute of Health.(10) Both changes were introduced blind to efficacy data and in agreement with the Independent Data Monitoring Committee (IDMC). The planned sample size remained unchanged since it still allowed 99% and 95% power to recognize 10% absolute reduction at 14 and 30-days, respectively, with a significant level of 2.5% for each co-primary endpoint.

Selection of patients

Patients were eligible if they had SARS-CoV-2 diagnosis done with real-time PCR and were hospitalized due to clinical/instrumental signs of pneumonia. Patients with oxygen saturation at rest in ambient air ≤93% or requiring oxygen support or mechanical ventilation either non-invasive or invasive (intubated less than 24 hours before registration) were eligible.

There was no limitation based on age and gender. Patients were not eligible in case of known hypersensitivity to tocilizumab, known active infections or other clinical conditions contraindicating tocilizumab that could not be treated or solved according to the judgment of the clinician, ALT/AST> 5 times the upper limit of the normality, neutrophils count <500/mmc, platelets <50.000/mmc, bowel diverticulitis or perforation.

Informed consent for participation in the study could be oral if a written consent was unfeasible. However if patients lack capacity to consent due to disease severity, and an authorized representative was not immediately available, treatment could be administered by the treating physician on her/his own responsibility. Consent to remain in the research had to be sought at the earliest opportunity.

Study populations

According to study design, five populations are defined: (a) intention to treat (ITT) phase 2, defined as all patients enrolled in the phase 2 study; (b) modified ITT (mITT) phase 2, defined as all patients of the ITT phase 2 population who received at least one dose of the study drug; (c) ITT validation population, defined as all patients consecutively and prospectively registered from March 20th to March 24th who were potentially eligible for the phase 2 study but exceeded the planned sample size; (d) mITT validation population, defined as all patients of the ITT validation population who received at least one dose of the study drug; (e) safety population, defined as (b) plus (d).

Objectives

The primary aim of the study was to estimate lethality rates at 14 and 30-days in the ITT phase 2 population. In this paper the same efficacy outcomes are reported for the other ITT and mITT populations. Description of adverse events in the safety population was a

key secondary endpoint. Other secondary efficacy endpoints, according to the protocol, will be reported in the future.

Treatment

Tocilizumab was administered at the dose of 8 mg/kg up to a maximum of 800 mg per dose. Such dose is the same approved by FDA for the treatment of CRS following CAR-T therapy.(6) A second administration of tocilizumab (same dose) was allowed 12 hours after the first if respiratory function had not recovered, at discretion of the Investigator. Tocilizumab was supplied at no cost by Roche Italy. Due to delayed availability of the drug and the rapidly increasing request, a variable delay between the date of patient registration and drug availability at the clinical center occurred. There was no contraindication for concomitant treatment of respiratory impairment; also, concomitant experimental antiviral treatment was allowed.

Adverse events reporting

All adverse events recorded from time of signature of informed consent, throughout the treatment and observation period up to 30-days following registration, had to be reported in the adverse event case report form, graded according to the corresponding CTCAE term (Version 5.0). Causality was assessed by the investigators only when reporting a Serious Adverse Event (SAE). CTCAE coded adverse events are reported for each category and term as the worst grade suffered by patients through the whole period of observation after treatment administration.

Statistical analysis

Statistical analysis is detailed in the Statistical Analysis plan for primary and secondary endpoints.(10) Briefly, differences between groups of baseline characteristics, collected at the time of registration, are assessed for categorical variables using χ^2 test and for continuous variables using Wilcoxon rank-sum test. Patients discharged to home or low-intensity care setting are considered alive at the end-date of the follow-up period of 30-days. Exact 97.5% Clopper-Pearson confidence intervals (CI) are calculated for the proportions of death at 14 and 30-days. Pre-specified null hypotheses at days 14 and 30 are tested by a two-sided binomial test with alpha level equal to 0.025. Efficacy outcomes (with exact 95% CI) are described in baseline subgroups defined by demographics and clinical variables and compared with exact chi square test.

The effect of treatment on the primary endpoints was further assessed by mean of a multivariable logistic regression model on the two populations combined. Age (≤60, 61-70, >70), gender, type of respiratory support (oxygen, non-invasive mechanical ventilation [NIMV], invasive mechanical ventilation [IMV]), PAO2/FIO2 ratio (≤100, 101-200, >200, missing/not evaluated), population (phase 2 or validation) and geographical area (Lombardia, Veneto, Emilia-Romagna, other Northern regions, Center, South and Islands) were entered as covariates. The interaction effects between treatment and the other covariates were tested one at a time by Wald test. Patients who received the drug four or more days after registration were excluded from multivariable analysis to rule out the immortal time bias expected with these subjects. Difference in the lethality rate between

treated and untreated patients was calculated within specific subgroups and 95% CI was calculated according to the method of Agresti and Caffo. (11)

Analysis is carried out using Stata version 14.0 (Stata Corp. College Station, TX, USA) and R version 3.6.1 (R Foundation for Statistical Computing, Vienna, Austria).

Study conduction and oversight

The study was sponsored by the National Cancer Institute of Naples and coordinated through the web-based platform of the Clinical Trial Unit. The IDMC was appointed on April 9th, 2020, including Aldo Maggioni (chief), Paolo Bruzzi, Antonio Pesenti, Valter Torri, and Giuseppe Traversa. Five IDMC meetings were arranged between April 10th, 2020 and May 12th, 2020.

Role of the funding source

No specific funding was available for this study. Tocilizumab was provided by the pharmaceutical company (Roche) free of charge. The National Cancer Institute of Naples was the sponsor of the study and had full property of data and full access to them and final responsibility for the decision to submit for publication.

Results

From March 19th to 24th, 2020,185 centers prospectively registered 1685 patients eligible for the present analyses (**Figure 1**); 13 cases were duplicated or withdrew consent, 399 patients remained in the phase 2 cohort and 1273 in the validation one. In both cohorts, in agreement with IDMC, we removed from analysis all patients recruited from uncooperative centers (i.e. those providing information on baseline characteristics and treatment for less than 25% of the enrolled patients). Therefore, ITT populations include 301 patients in the phase 2 and 920 in the validation cohort. In the phase 2 population, 21 patients found ineligible a posteriori (12 intubated more than 24 hours before registration, 7 registered after being already treated, 2 with both violations) remained in the ITT cohort.

Phase 2 and validation cohorts differ for geographical distribution of centers (**Figure A1)** and severity of the respiratory disease, with a higher percentage of patients undergoing invasive mechanical ventilation and with a worse profile of PaO2/FiO2 in the phase 2 cohort. Other baseline characteristics are summarized in **Table 1 and Tables A1 to A3.**

Due to delayed drug availability, treatment was given to only 59.8% of patients, in phase 2, and 59.5% in the validation cohort. Median delay to treatment administration was 2 days in phase 2 and one day in the validation cohort. In both cohorts, 23% of treated patients received tocilizumab after 4 or more days from registration. The most frequent reason for not giving the drug (once it was available) was clinical improvement (**Table A4**). In both

cohorts, patients with worse respiratory function were preferentially treated, as shown by the distribution of PaO2/FiO2 ratio and of type of respiratory support, leading to substantial differences in characteristics of the untreated subjects of the two cohorts. In the phase 2 cohort younger patients were also preferentially treated (**Table 2**).

Overall, 67 (22.3%) and 158 (17.2%) deaths were reported in the ITT phase 2 and ITT validation cohorts. As expected given the above characteristics of patients, prognosis was worse in the phase 2 cohort, both in the ITT and mITT populations mainly because the untreated patients in the phase 2 had higher probability of death with respect to the corresponding untreated patients in the validation cohort (**Figure A3**).

In the ITT phase 2 population, lethality rate was 18.4% (97.5% CI 13.6-24.0) at 14-days and 22.4% (97.5% CI 17.2-28.3) at 30-days. The null hypothesis was rejected at 30-days but not at 14-days (P<0.001and P=0.52, respectively). At both time points, lethality rates were lower in the mITT population (15.6% and 20.0%). In the validation cohort, lethality rates were consistently lower than the predefined null hypothesis both at 14 and 30-days in the ITT (11.4% and 18.4%) and mITT (10.9% and 20.0%) populations (**Table 3**).

Lethality rates at 14-days were lower for patients receiving treatment 4 or more days after registration, because of the immortal time bias, that disappeared at 30-days, both in phase 2 and validation cohorts. In phase 2, risk of death was significantly increasing in patients older and with worse PaO2/FiO2 ratio (**Figure 2a and Table A5**). Similar findings were observed in the validation cohort, where prognosis was also significantly worsened in patients needing a more intensive respiratory support and in patients suffering mild or worse hypertension (**Figure 2b and Table A5**). At multivariable analysis no significant interaction was found between the effect of treatment and age, gender, PaO2/FiO2 ratio, geographic location and phase 2 vs validation population (data not shown). On the contrary, a significant interaction was found (**Table A6**) with required respiratory support, interaction test p-values being equal to 0.02 and 0.045 at 14 and 30 days, respectively. Specifically, treatment significantly reduced mortality only in subjects not requiring mechanical respiratory support within 24 hours from registration, while no effect was observed in patients who required invasive or non-invasive mechanical ventilation. At 14 and 30 days, respectively, OR in the former patients were equal to 0.35 (95% CI 0.18-0.70) and 0.47 (95% CI 0.26-0.87) and absolute reductions equal to 7.7% and 6.2% (**Figure A4 panels A and B**). The analysis also confirmed the negative prognostic effect of older age and low PaO2/FiO2 ratio, and the mortality differences between the two study populations.

Adverse events in 628 of 708 patients receiving treatment are summarized in **table A6**. At least one grade >0 adverse event was reported in 40.8% of patients. Of note, 68 deaths (10.8%) were categorized within adverse events scale. Causality between such deaths and treatment was described as possible only in one of the 35 cases of respiratory failure. All the other fatal adverse events were reported as unlikely or not related to treatment administration. Seven out of 8 fatal infections were specified as COVID pneumonia. Adverse events that may represent specific side effects of tocilizumab are allergic reactions (3 cases) and ALT or AST increase (reported in 10.5% and 9.1% respectively) that was severe (grade 3 or 4) in around 3% of cases.

Discussion

The primary analysis of TOCIVID-19 suggests that tocilizumab may reduce lethality at 30-days, although its impact at 14-days seems less relevant. Multivariable analysis supports that the treatment is effective in patients not requiring mechanical respiratory support. The adverse event profile does not generate clinically relevant warning, possibly because of the severity of clinical symptoms related to the underlying pathologic condition. These results support performing phase 3 clinical trials to confirm the benefit on mortality. Three ongoing randomized trials are comparing tocilizumab vs placebo (ChiCTR2000029765, NCT04320615, NCT04381936) and another one is comparing immediate vs delayed tocilizumab (NCT04346355).

To our knowledge TOCIVID-19 is the largest study on the effect of tocilizumab and the only one prospectively assessing mortality. Only retrospective or observational data have been reported, with prevalently positive results.(8, 12-16) However, our study has several limitations that deserve discussion for a better interpretation of findings.

The first limitation is the single-arm study design, which prevents firm conclusions. We are aware of weakness of non-randomized design without a control group, in a new disease setting, where no established a priori estimates are available. However, we think that a randomized controlled trial was unfeasible for many reasons. There was a tremendous pressure to have the drug available, due to a widespread media diffusion of positive expectations and to the increasing number of patients hospitalized for the disease, as confirmed by the massive registration of centers as soon as the study began. Thus, obtaining a proper informed consent to randomization would have been extremely difficult also due to patients' condition and clinical burden. Finally, developing a placebo was impossible, and, at least in principle, the risk of cross-over from the control to the experimental arm within a non-blind study would have been high, reducing the validity of the randomized trial itself.

A critical issue of the single-arm design was the definition of the null hypotheses to be tested, due to lack of suitable information at the start of the study. We actually defined them, blind to any result, based on indirect and partial information from Italian institutions.(10) Although we slightly reduced our estimates following the advice of the IDMC, we cannot yet be sure that our assumptions are unbiased. A recent study, with data on near 43.000 patients coming from three Italian regions, reports higher lethality at 14-days (22.0%) and lower at 30-days (27.6%) compared to our null hypotheses; assuming these estimates our results would be slightly worse but still clinically significant at 30-days.(17)

Further, the case-mix of our populations was affected by geographical distribution and by the strategy of the physicians who registered patients in the trial. This is revealed by the evident prognostic difference between phase 2 and validation cohort, the latter being better than the former. It is also surprising that untreated patients in the validation cohort fared much better than untreated ones in phase 2, owing to a likely selection bias of physicians who preferentially treated subjects with worse clinical conditions, thus leading to caution in the interpretation of findings of the validation cohort.

A major issue of our study was the discrepancy between drug availability (notwithstanding the commitment of the pharma company) and the extremely high request due to the rapid recruitment rate. As a consequence, two biases could arise: the indication bias, occurring when patients with worse prognosis were preferentially treated, and the immortal time bias, occurring in patients where treatment was delayed, since only subjects surviving longer could receive the drug. Actually, the latter bias was evident at 14-days, but not at 30-days. To rule out the latter bias, patients who received the drug later than 3 days from registration were removed from the multivariable analysis testing the effect of treatment by confounding or prognostic covariates.

Last, we had many missing data, particularly in the validation cohort, for several reasons: massive involvement and stress of physicians in emergency patient care; paucity or absence of data-managers in participating centers; quarantine imposed to paper charts in some centers; impracticality of peripheral monitoring; lack of training of researchers to the web platform; slow web connections with the study platform due to unexpectedly high information loading volume. In agreement with IDMC, we removed uncooperative centers that provided baseline information for less than 25% of patients, but still we cannot be confident that missing data are at random.

Nevertheless, we think that our study has some strengths. As mentioned above, TOCIVID-19 is the first academic trial promoted in Italy, the largest in terms of centers and patients (being available for the whole Italian territory), and most importantly the only one assessing a hard endpoint like mortality. Moreover, the study implemented a hypothesis driven design in a context where off label use of the drug was increasing. In addition, notwithstanding the above discussed limitations, the internal validation, allowed by a companion prospective cohort, contributed to better interpretation of the results. Further analyses will focus on secondary outcomes (e.g. respiratory outcomes, predictive and prognostic factors, epidemiology insights) and on a larger number of patients.

Declaration of interests

Dr. Perrone reports grants, personal fees and non-financial support from Bayer; grants and personal fees from Incyte, Astra Zeneca, Pierre Fabre; personal fees from Celgene, Janssen Cilag, Roche, Pfizer, Sandoz, outside the submitted work.

Dr. Piccirillo reports grants and personal fees from AstraZeneca; grants from Roche; personal fees from Daichii Sankyo, GSK, MSD; non-financial support from Bayer, outside the submitted work.

Dr. Ascierto reports grants and personal fees from BMS, Roche-Genentech, Array; personal fees and other from MSD; personal fees from Novartis, Merck Serono, Pierre Fabre, Incyte, Genmab, NewLink Genetics, Medimmune, AstraZeneca, Syndax, Sun Pharma, Sanofi, Idera, Ultimovacs, Sandoz, Immunocore, 4SC, Alkermes, Italfarmaco, Nektar, Boehringer-Ingelheim, outside the submitted work.

Dr. Salvarani reports grants and personal fees from Roche; personal fees from Sanofi-Genzyme, Abbvie, Pfizer, Eli-Lilly, Novartis, outside the submitted work.

Dr. Castelli reports grants from Gilead, ViiV, GSK, Janssen, Eiger, Roche, Gilead, outside the submitted work.

Dr. Gravina reports non-financial support from Pfizer, outside the submitted work.

Dr. Lichtner reports grants from Gilead; personal fees from Abbvie, Merck, Janseen, Angelini, outside the submitted work.

Authors' contribution

Study design: FP, MCP, PAA, CS, PC, CG.

Statistical analysis: LA, PC, CG.

Data interpretation and final approval of text: FP, MCP, PAA, CS, RP, AMM, PP, LF, MMMT, DR, FB, PB, NS, FC, MLM, ML, CCal, NDS, LA, MCa, MCo, GD, NF, FF, MM, VM, CM, EAN, GB, CCar, PG, AG, CS, LA, PC, CG

Writing of the draft manuscript: FP, MCP, PC, CG.

Legends of figures

Figure 1. Study flow

Figure 2. Estimated lethality rates at 14 and 30-days by baseline characteristics of patients in the phase 2 (figure 2a - top) and validation (figure 2b - bottom) ITT populations. Red dash lines represent lethality rates under null hypotheses.

References

1. Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N Engl J Med. 2020.
2. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020.
3. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708-20.
4. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.
5. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-33.
6. Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, et al. FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome. Oncologist. 2018;23(8):943-7.
7. Scott LJ. Tocilizumab: A Review in Rheumatoid Arthritis. Drugs. 2017;77(17):1865-79.
8. Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020.
9. Piccirillo M, Ascierto P, Atripaldi L, Cascella M, Costantini M, Dolci G, et al. Multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia. Epidemiologia & Prevenzione 2020:www.repo.epiprev.it/1604
10. Chiodini P, Arenare L, Piccirillo M, Perrone F, Gallo C. A phase 2, open label, multicenter, single arm study of tocilizumabon the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia (TOCIVID-19 trial): Statistical Analysis Plan. Epidemiologia & Prevenzione 2020:www.repo.epiprev.it/1610.
11. Agresti A, Caffo B. Simple and Effective Confidence Intervals for Proportions and Differences of Proportions Result from Adding Two Successes and Two Failures. The American Statistician. 2000;54(4):280-8.
12. Alattar R, Ibrahim TBH, Shaar SH, Abdalla S, Shukri K, Daghfal JN, et al. Tocilizumab for the treatment of severe coronavirus disease 2019. J Med Virol. 2020.
13. Capra R, De Rossi N, Mattioli F, Romanelli G, Scarpazza C, Sormani MP, et al. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. Eur J Intern Med. 2020.
14. Colaneri M, Bogliolo L, Valsecchi P, Sacchi P, Zuccaro V, Brandolino F, et al. Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE). Microorganisms. 2020;8(5).
15. Klopfenstein T, Zayet S, Lohse A, Balblanc JC, Badie J, Royer PY, et al. Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients. Med Mal Infect. 2020.
16. Toniati P, Piva S, Cattalini M, Garrafa E, Regola F, Castelli F, et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. Autoimmun Rev. 2020:102568.
17. Giorgi Rossi P, Ferroni E, Spila Alegiani S, Leoni O, Pitter G, Cereda D, et al. Survival of hospitalized COVID-19 patients in Northern Italy: a population-based cohort study by the ITA-COVID19 Network. 2020:2020.05.15.20103119.

Table 1. Baseline characteristics of patients in the ITT phase 2 and validation cohorts

	ITT Phase 2	ITT Validation
	N=301	N=920
Geographic area – no. (%)		
Lombardia	136 (45.2%)	346 (37.6%)
Veneto	65 (21.6%)	41 (4.5%)
Emilia Romagna	37 (12.3%)	142 (15.4%)
Other Northern regions	-	91 (9.9%)
Center	39 (13.0%)	186 (20.2%)
South and Islands	24 (8.0%)	114 (12.4%)
Age – no. (%)		
≤60	122 (40.5%)	375 (40.8%)
61-70	107 (35.5%)	263 (28.6%)
71+	72 (23.9%)	282 (30.7%)
Female sex – no. (%)	59 (19.6%)	200 (21.7%)
Ethnic group – no. (%)		
Caucasian	271 (97.1%)	853 (97.7%)
Asiatic	3 (1.1%)	2 (0.2%)
Other	5 (1.8%)	18 (2.1%)
Unknown	22	47
Body Mass Index – no. (%)		
Underweight/normal (<25)	75 (29.0%)	192 (27.0%)
Overweight/obese (25+)	184 (71.0%%)	518 (73.0%)
Unknown	42	210
Previous/actual smoker – no. (%)	51 (22.2%)	214 (29.2%)
Unknown	71	188
Antiflu 2019 vaccination – no. (%)	54 (25.0%)	121 (20.3%)
Unknown	85	325
Initial respiratory support* – no. (%)		
Oxygen supplementation	146 (48.5%)	468 (50.9%)
NIMV	106 (35.2%)	359 (39.0%)
IMV	49 (16.3%)	93 (10.1%)
PaO2/FiO2 ratio - Median (IQR)	136 (93, 198)	154 (103, 218)
PaO2/FiO2 ratio – no. (%)		
<100	55 (32.4%)	129 (24.1%)
101-200	76 (44.7%)	244 (45.5%)
201-300	32 (18.8%)	116 (21.6%)
>300	7 (4.1%)	47 (8.8%)
Missing or not tested	131	384
Comorbidities (mild or worse) – no. (%)		
Heart disease	62 (21.6%)	150 (18.1%)
Hypertension	147 (51.2%)	389 (47.0%)
Diabetes	34 (11.8%)	138 (16.7%)
Unknown	14	93

	ITT Phase 2	ITT Validation
	N=301	N=920
Concurrent treatment, no. (%)		
Antiretroviral	179 (63.5%)	549 (66.9%)
Hydroxy-chloroquine	205 (72.7%)	627 (76.4%)
Antibiotics	117 (41.5%)	421 (51.3%)
Steroids	61 (21.6%)	277 (33.7%)
LMW heparin	64 (22.7%)	158 (19.2%)
Unknown	19	99
C-reactive protein – Median (IQR)	37.6 (14.7, 120.0)	36.3 (13.7, 137.0)
Missing or not tested	181	255

Table 2. Distribution of baseline characteristics of patients collected at registration by treatment administration

	Phase 2			Validation		
	Treated (n=180)	Not treated (n=121)	P	Treated (n=528)	Not treated (n=360)	P
Geographic area – no. (%)			***<0.001***			*0.30*
Lombardia	94 (52.2%)	42 (34.7%)		195 (36.9%)	140 (38.9%)	
Veneto	14 (7.8%)	51 (42.1%)		28 (5.3%)	12 (3.3%)	
Emilia Romagna	29 (16.1%)	8 (6.6%)		76 (14.4%)	65 (18.1%)	
Other Northern regions	-	-		51 (9.7%)	40 (11.1%)	
Center	23 (12.8%)	16 (13.2%)		107 (20.3%)	61 (16.9%)	
South and Islands	20 (11.1%)	4 (3.3%)		71 (13.4%)	42 (11.7%)	
Age – no. (%)			***0.04***			0.22
≤60	79 (43.9%)	43 (35.5%)		209 (39.6%)	156 (43.3%)	
61-70	67 (37.2%)	40 (33.1%)		148 (28.0%)	107 (29.7%)	
71+	34 (18.9%)	38 (31.4%)		171 (32.4%)	97 (26.9%)	
Female sex – no. (%)	31 (17.2%)	28 (23.1%)	0.20	108 (20.5%)	85 (23.6%)	0.26
Ethnic group – no. (%)			0.42			0.51
Caucasian	170 (97.1%)	101 (97.1%)		494 (97.4%)	333 (97.9%)	
Asiatic	1 (0.6%)	2 (1.9%)		2 (0.4%)	0 (0.0%)	
Other	4 (2.3%)	1 (1.0%)		11 (2.2%)	7 (2.1%)	
Unknown	5	17		21	20	
Body Mass Index – no. (%)			0.14			0.43
Underweight/normal	40 (24.8%)	35 (35.7%)		112 (27.3%)	73 (26.1%)	
Overweight	83 (51.6%)	46 (46.9%)		192 (46.7%)	144 (51.4%)	
Obese	38 (23.6%)	17 (17.3%)		107 (26.0%)	63 (22.5%)	
Unknown	19	23		117	80	
Previous/actual smoker – no. (%)	33 (22.4%)	18 (21.7%)	0.89	130 (30.2%)	79 (27.9%)	0.52
Unknown	33	38		97	77	
Antiflu 2019 vaccination – no. (%)	31 (21.5%)	23 (31.9%)	0.10	75 (21.8%)	44 (18.5%)	0.33
Unknown	36	49		184	122	
Initial respiratory support– no. (%)			***0.003***			***<0.001***
Oxygen supplement	73 (40.6%)	73 (60.3%)		223 (42.2%)	223 (61.9%)	
NIMV	74 (41.1%)	32 (26.4%)		238 (45.1%)	112 (31.1%)	
IMV	33 (18.3%)	16 (13.2%)		67 (12.7%)	25 (6.9%)	
PaO2/FiO2 ratio– no. (%)			0.08			***<0.001***
≤100	36 (33.6%)	19 (30.2%)		91 (25.9%)	30 (18.3%)	
101-200	53 (49.5%)	23 (36.5%)		170 (48.4%)	66 (40.2%)	
201-300	14 (13.1%)	18 (28.6%)		68 (19.4%)	44 (26.8%)	
>300	4 (3.7%)	3 (4.8%)		22 (6.3%)	24 (14.6%)	
Unknown	73	58		177	196	
Heart disease – no. (%)	31 (17.8%)	31 (27.4%)	0.053	99 (19.4%)	48 (15.6%)	0.17
Unknown	6	8		18	53	
Hypertension – no. (%)	92 (52.9%)	55 (48.7%)	0.49	242 (47.5%)	141 (45.9%)	0.67
Unknown	6	8		18	53	
Diabetes – no. (%)	23 (13.2%)	11 (9.7%)	0.37	84 (16.5%)	51 (16.6%)	0.96
Unknown	6	8		18	53	
Anti-retroviral – no. (%)	112 (65.5%)	67 (60.4%)	0.38	336 (66.3%)	207 (68.1%)	0.59
Unknown	9	10		21	56	

	Phase 2			Validation		
	Treated (n=180)	**Not treated (n=121)**	**P**	**Treated (n=528)**	**Not treated (n=360)**	**P**
Hydroxy-chloroquine – no. (%)	129 (75.4%)	76 (68.5%)	0.20	387 (76.3%)	230 (75.7%)	0.83
Unknown	9	10		21	56	
Antibiotics – no. (%)	84 (49.1%)	33 (29.7%)	***<0.001***	266 (52.5%)	151 (49.7%)	*0.44*
Unknown	9	10		21	56	
Steroids – no. (%)	40 (23.4%)	21 (18.9%)	*0.37*	171 (33.7%)	103 (33.9%)	*0.96*
Unknown	9	10		21	56	
LMW heparin – no. (%)	44 (25.7%)	20 (18.0%)	*0.13*	110 (21.7%)	48 (15.8%)	***0.04***
Unknown	9	10		21	56	
C-reactive protein – median (IQR)	30 (13, 116)	73 (17, 122)	*0.06*	31 (14, 132)	57 (14, 144)	*0.38*
Unknown	34	29		102	128	

Table 3. Efficacy analysis

	Phase 2	Validation
14 days intention-to-treat		
No. of events/no. of patients at risk	55/299	101/884
Lethality rate, % (97.5% CI)	**18.4% (13.6-24.0)**	**11.4% (9.1-14.0)**
P value (P0=20%)	**0.52**	**<0.001**
14 days modified intention-to-treat		
No. of events/no. of patients at risk	28/180	56/515
Lethality rate, % (95% CI)	15.6% (10.6-21.7)	10.9% (8.3-13.9)
30 days intention-to-treat		
No. of events/no. of patients at risk	67/299	158/858
Lethality rate, % (97.5% CI)	**22.4% (17.2-28.3)**	**18.4% (15.5-21.6)**
P value (P0=35%)	**<0.001**	**<0.001**
Median time of death, days (IQR)	8 (4-14)	11 (4-18)
30 days modified intention-to-treat		
No. of events/no. of patients at risk	36/180	99/495
Lethality rate, % (95% CI)	20.0% (14.4-26.6)	20.0% (16.6-23.8)


1685 registered prospectively March 19 to 24, 2020, and eligible for the present analysis
7 duplicated
6 consent withdrawal
399 Phase 2 cohort
1273 Validation cohort
98 excluded
(enrolled by 12 centres collecting data for <25% of cases)
353 excluded
(enrolled by 65 centres collecting data for <25% of cases)
301 ITT Phase 2 cohort
2/2 missing outcome at 14/30 days
920 ITT Validation cohort
36/62 missing outcome at 14/30days
0 treatment data missing
121 did not receive treatment
32 treatment data missing
360 did not receive treatment
180 mITT Phase 2 cohort
0/0 missing outcome at 14/30 days
528 mITT Validation cohort
13/33 missing outcome at 14/30 days
708 Safety population
628 data available

Figure 1


Phase 2 Lethality Rate
14 DAYS
P
30 DAYS
P
All Patients
Treatment
0·23
0·47
≤3 days
≥4 days
Not treated
Geographic area
0·91
0·93
Lombardia
Veneto
Emilia Romagna
Other northern
Centre
South and Island
Age
<0·001
<0·001
≤60
61-70
71+
Gender
1·00
0·73
Female
Male
Body Mass Index
0·73
1·00
Underweight/normal
Overweight/Obese
Smoking habit
0·84
0·57
Never smoker
Previous/actual smoker
Initial respiratory support
0·76
0·47
Oxygen supplement
NIMV
IMV
PaO2/FiO2 ratio
0·006
0·001
≤100
101-200
>200
Heart disease
0·06
0·06
None
Mild or more
Hypertension
0·06
0·11
None
Mild or more
Diabetes
0·33
0·12
None
Mild or more
C-reactive protein
0·48
0·41
≤37
>37
0
10
20
30
40
50
60
0
10
20
30
40
50
60

Figure 2a


Validation Lethality Rate
14 DAYS
P
30 DAYS
P
All Patients
Treatment
0·16
0·14
≤3 days
≥4 days
Not treated
Geographic area
0·09
0,14
Lombardia
Veneto
Emilia Romagna
Other northern
Centre
South and Island
Age
<0·001
<0·001
≤60
61-70
71+
Gender
0·52
0·24
Female
Male
Body Mass Index
0·69
0·38
Underweight/normal
Overweight/Obese
Smoking habit
0·89
0·29
Never smoker
Previous/actual smoker
Initial respiratory support
0·001
<0·001
Oxygen supplement
NIMV
IMV
PaO2/FiO2 ratio
0·01
<0·001
≤100
101—200
>200
Heart disease
0·19
0·15
None
Mild or more
Hypertension
<0·001
<0·001
None
Mild or more
Diabetes
0·37
0·27
None
Mild or more
C-reactive protein
0·46
0·68
≤37
>37
0
10
20
30
40
50
60
0
10
20
30
40
50
60

Figure 2b

Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 trial

Appendix

Summary

Table A1. Distribution of patients by participating centres in the ITT phase 2 and validation cohorts 2

Figure A1. Geographic distribution of centers (red) and patients (green) in the phase 2 (top) and validation (bottom) cohorts 3

Table A2. Distribution of comorbidities (mild grade or worse) in the ITT phase 2 and validation cohorts 4

Table A3. Distribution of concurrent treatments in the ITT phase 2 and validation cohorts 5

Table A4. Details of treatment compliance 6

Figure A2. Probability of death in the phase 2 (blue) and validation cohorts (orange) in the ITT (top) , mITT (center) and untreated (bottom) populations. 7

Table A5. Lethality rates according to subgroups in ITT phase 2 and validation 8

Table A6. Worst per patient adverse events reported after treatment with tocilizumab by CTCAE grade..... 9

Table A7. Multivariable logistic regression 11

Figure A3. Relative (Odds Ratio of death, panel A) and absolute (difference in lethality rate, panel B) measures of treatment effect by required respiratory support at 14 and 30 days. 12

List of participating centers and Co-Investigators..... 12

Table A1. Distribution of patients by participating centres in the ITT phase 2 and validation **cohorts**

	Phase 2 ITT N=301	**Validation ITT N=920**
Size of center by rank of registered patients, n (%)		
Large (>20 pts)	147 (48.8%) *[from 4 centres]*	232 (25.2%) *[from 7 centres]*
Medium (6 to 20 pts)	107 (35.6%) *[from 11 centres]*	465 (50.6%) *[from 49 centres]*
Small (1 to 5 pts)	47 (15.6%) *[from 24 centres]*	223 (24.2%) *[from 90 centres]*
Specialty of the participating centre, n (%)		
Infectious Disease	204 (67.8%)	341 (37.1%)
Internal Medicine (including subspecialties)	71 (23.6%)	378 (41.1%)
Intensive/Subintensive Care	22 (7.3%)	116 (12.6%)
Emergency/other	4 (1.3%)	85 (9.2%)
Macroregion of the participating centre, n (%)		
North	238 (79.1%)	620 (67.4%)
Centre	39 (13.0%)	186 (20.2%)
South and Islands	24 (8.0%)	114 (12.4%)
Region of the participating centre, n (%)		
Lombardia (57 centres)	136 (45.2%)	346 (37.6%)
Emilia-Romagna (25 centres including S.Marino)	37 (12.3%)	142 (15.4%)
Veneto (16 centres)	65 (21.6%)	41 (4.5%)
Piemonte (10 centres)	0 (0.0%)	56 (6.1%)
Liguria (4 centres)	0 (0.0%)	19 (2.1%)
PA Trento (1 centre)	0 (0.0%)	4 (0.4%)
PA Bolzano (2 centres)	0 (0.0%)	9 (1.0%)
Friuli Venezia Giulia (1 centre)	0 (0.0%)	3 (0.3%)
Lazio (10 centres)	8 (2.7%)	88 (9.6%)
Toscana (15 centres)	16 (5.3%)	36 (3.9%)
Marche (9 centres)	3 (1.0%)	55 (6.0%)
Umbria (2 centres)	12 (4.0%)	7 (0.8%)
Sicilia (5 centres)	1 (0.3%)	43 (4.7%)
Campania (13 centres)	15 (5.0%)	35 (3.8%)
Puglia (9 centres)	8 (2.7%)	19 (2.1%)
Abruzzo (3 centres)	0 (0.0%)	12 (1.3%)
Sardegna (1 centre)	0 (0.0%)	1 (0.1%)
Calabria (2 centres)	0 (0.0%)	4 (0.4%)

Figure A1. Geographic distribution of centers (red) and patients (green) in the phase 2 (top) and validation (bottom) cohorts



Table A2. Distribution of comorbidities (mild grade or worse) in the ITT phase 2 and validation cohorts

	Phase 2 ITT N=301	**Validation ITT N=920**
Unknown	*14*	*93*
Heart disease, n (%)	62 (21.6%)	150 (18.1%)
Hypertension, n (%)	147 (51.2%)	389 (47.0%)
Vascular disease, n (%)	26 (9.1%)	72 (8.7%)
Respiratory disease, n (%)	26 (9.1%)	93 (11.2%)
ENT, n (%)	9 (3.1%)	31 (3.7%)
Upper GI tract disease, n (%)	16 (5.6%)	61 (7.4%)
Lower GI tract disease, n (%)	12 (4.2%)	34 (4.1%)
Liver disease, n (%)	14 (4.9%)	27 (3.3%)
Kidney disease, n (%)	20 (7.0%)	44 (5.3%)
Genito-urinary disease, n (%)	16 (5.6%)	82 (9.9%)
Musculo-skeletal-skin disease, n (%)	18 (6.3%)	42 (5.1%)
Nervous system disease, n (%)	13 (4.5%)	51 (6.2%)
Diabetes, n (%)	34 (11.8%)	138 (16.7%)
Psychiatric disorders, n (%)	19 (6.6%)	59 (7.1%)
Cancer, n (%)		
Present disease	6 (3.8%)	24 (4.6%)
Past disease	14 (10.1%)	54 (11.7%)

Table A3. Distribution of concurrent treatments in the ITT phase 2 and validation cohorts

Class of drug or drug	Phase 2 ITT N=301	Validation ITT N=920
Unknown	19	99
Antivirals, n (%)		
Anti-retroviral	179 (63.5%)	549 (66.9%)
Lopinavir/Ritonavir	148 (52.5%)	409 (49.8%)
Remdesivir	1 (0.4%)	1 (0.1%)
Anti-HBV	1 (0.4%)	1 (0.1%)
Anti-HCV	0 (0.0%)	1 (0.1%)
Anti-flu	0 (0.0%)	4 (0.5%)
(Hydroxy)chloroquine, n (%)	205 (72.7%)	627 (76.4%)
Colchicine, n (%)	0 (0.0%)	3 (0.4%)
Immune suppressor, n (%)	1 (0.4%)	7 (0.9%)
Antibiotics, n (%)	117 (41.5%)	421 (51.3%)
Azythromicin	51 (18.1%)	169 (20.6%)
Ceftriaxone	69 (24.5%)	268 (32.6%)
Linezolid	2 (0.7%)	8 (1.0%)
Steroids, n (%)	61 (21.6%)	277 (33.7%)
LMW heparin, n (%)	64 (22.7%)	158 (19.2%)
Anti-coagulants, n (%)	16 (5.7%)	35 (4.3%)
Anti-aggregating, n (%)	31 (11.0%)	74 (9.0%)
Anti-diabetics, n (%)	23 (8.2%)	55 (6.7%)
Anti-hypertension, n (%)	61 (21.6%)	138 (16.8%)
ACE inhibitors	11 (3.9%)	18 (2.2%)
Sartane	17 (6.0%)	32 (3.9%)

NB. Missing cases are not considered in percentage calculation

Table A4. Details of treatment compliance

	Phase 2 ITT N=301	Validation ITT N=920
Unknown information	*0*	*32*
Tocilizumab 1st dose, n (%)		
Not administered	121 (40.2%)	360 (40.5%)
Death	8 (6.6%)	22 (6.1%)
Improvement	37 (30.6%)	162 (45.0%)
Worsening	9 (7.4%)	12 (3.3%)
Moved to other unit	8 (6.6%)	12 (3.3%)
Other	5 (4.1%)	19 (5.3%)
Lack of drug	4 (3.3%)	37 (10.3%)
Unknown	50 (41.3%)	96 (26.7%)
Administered	180[a] (59.8%)	528[b] (59.5%)
≤3 days from registration	138 (76.7%)	404 (76.5%)
≥4 days from registration	42 (23.3%)	124 (23.5%)
Median days (IQR) to administration	2 (1-3)	1 (0-3)
Tocilizumab 2nd dose administered, n (%)		
Not administered	137 (45.5%)	333 (37.5%)
Administered	164 (54.5%)	555 (62.5%)

[a] 7 cases subcutaneous; [b] 39 cases subcutaneous

Figure A2. Probability of death in the phase 2 (blue) and validation cohorts (orange) in the ITT (top) , mITT (center) and untreated (bottom) populations.



Table A5. Lethality rates according to subgroups in ITT phase 2 and validation

	Phase 2		Validation	
	Lethality rate, % (95% CI)		Lethality rate, % (95% CI)	
	14 days	30 days	14 days	30 days
Treatment administration				
≤3 days from registration	16.7 (10.9-24.0)	19.6 (13.3-27.2)	12.2 (9.2-15.9)	19.7 (15.8-24.1)
≥4 days from registration	11.9 (4.0-25.6)	21.4 (10.3-36.8)	6.5 (2.8-12.4)	21.0 (14.1-29.4)
Not treated	22.7 (15.5-31.3)	26.1 (18.4-34.9)	12.7 (9.5-16.7)	17.0 (13.2-21.4)
P	*0.23*	*0.47*	*0.16*	*0.53*
Geographic area				
Lombardia	20.1 (13.7-27.9)	23.9 (16.9-32.0)	14.7 (11.1-19)	21.6 (17.2-26.5)
Veneto	16.9 (8.8-28.3)	20 (11.1-31.8)	7.5 (1.6-20.4)	19.4 (8.2-36.0)
Emilia Romagna	13.5 (4.5-28.8)	18.9 (8-35.2)	12.8 (7.7-19.4)	22.1 (15.6-29.9)
Other northern	-	-	12.6 (6.5-21.5)	14.3 (7.6-23.6)
Centre	17.9 (7.5-33.5)	25.6 (13-42.1)	7.7 (4.3-12.6)	15.3 (10.4-21.5)
South and Islands	20.8 (7.1-42.2)	20.8 (7.1-42.2)	6.4 (2.6-12.8)	12.1 (6.6-19.9)
P	*0.91*	*0.93*	*0.09*	*0.14*
Age				
≤60	2.5 (0.5-7.0)	8.2 (4.0-14.6)	4.5 (2.6-7.2)	7.8 (5.2-11.1)
61-70	19.8 (12.7-28.7)	22.6 (15.1-31.8)	7.4 (4.5-11.3)	14.9 (10.7-20.0)
71+	43.7 (31.9-56.0)	46.5 (34.5-58.7)	24.4 (19.4-30.0)	35.7 (29.9-41.9)
P	***<0.001***	***<0.001***	***<0.001***	***<0.001***
Gender				
Female	18.6 (9.7-30.9)	20.3 (11-32.8)	9.9 (6.1-15.1)	15.3 (10.4-21.3)
Male	18.3 (13.6-23.8)	22.9 (17.8-28.8)	11.8 (9.5-14.5)	19.3 (16.4-22.4)
P	*0.99*	*0.73*	*0.52*	*0.24*
Body Mass Index				
Underweight/normal	17.3 (9.6-27.8)	22.7 (13.8-33.8)	12.4 (8-18.1)	21.5 (15.7-28.3)
Overweight/obese	19.7 (14.2-26.2)	22.4 (16.6-29.1)	11.2 (8.6-14.3)	18.2 (14.9-22)
P	*0.73*	*0.99*	*0.69*	*0.38*
Smoking habit				
Never smoker	19.2 (13.7-25.8)	21.5 (15.7-28.3)	11.0 (8.4-14.1)	18.1 (14.8-21.9)
Previous or actual smoker	21.6 (11.3-35.3)	25.5 (14.3-39.6)	11.7 (7.6-16.8)	21.7 (16.2-28.1)
P	*0.84*	*0.57*	*0.89*	*0.29*
Initial respiratory support				
Oxygen supplement	16.6 (10.9-23.6)	20 (13.8-27.4)	7.5 (5.2-10.3)	10.8 (8-14.0)
NIMV	20.0 (12.8-28.9)	22.9 (15.2-32.1)	14.8 (11.2-18.9)	22.9 (18.5-27.8)
IMV	20.4 (10.2-34.3)	28.6 (16.6-43.3)	17.8 (10.5-27.3)	40 (29.5-51.2)
P	*0.76*	*0.47*	***0.001***	***<0.001***
PaO2/FiO2				
≤100	27.3 (16.1-41.0)	34.5 (22.2-48.6)	15.6 (9.8-23.1)	26.6 (19.1-35.3)
101-200	14.5 (7.5-24.4)	18.4 (10.5-29.0)	7.9 (4.8-12.1)	15.7 (11.3-21.1)
>200	2.6 (0.1-13.8)	2.6 (0.1-13.8)	5.7 (2.6-10.5)	6.5 (3.1-11.5)
P	***0.006***	***0.001***	***0.01***	***<0.001***
Heart disease				
None	14.8 (10.4-20.1)	18.8 (13.9-24.6)	10.0 (7.9-12.6)	17.1 (14.3-20.3)
Mild or worse	25.8 (15.5-38.5)	30.6(19.6-43.7)	14 (8.9-20.6)	22.6 (16.1-30.3)
P	*0.06*	*0.06*	*0.19*	*0.15*
Hypertension				
None	12.9 (7.8-19.6)	17.1 (11.3-24.4)	6.3 (4.2-9.1)	11.2 (8.4-14.6)
Mild or worse	21.4 (15-29.0)	25.5 (18.6-33.4)	15.8 (12.3-19.9)	26.2 (21.7-31)
P	*0.06*	*0.11*	***<0.001***	***<0.001***
Diabetes				
None	16.3 (12.0-21.5)	19.9 (15.2-25.4)	10.3 (8.1-12.8)	17.4 (14.6-20.6)
Mild or worse	23.5 (10.7-41.2)	32.4 (17.4-50.5)	13.2 (8.0-20.1)	21.8 (15.1-29.8)
P	*0.33*	*0.12*	*0.37*	*0.27*
C-reactive protein				
≤37	13.7 (8.0-21.3)	16.2 (10.1-24.2)	10.6 (7.5-14.4)	18.1 (14-22.7)
>37	17.5 (11.2-25.5)	20.8 (14.0-29.2)	12.5 (9.1-16.7)	19.6 (15.3-24.4)
P	*0.48*	*0.41*	*0.46*	*0.68*

Table A6. Worst per patient adverse events reported after treatment with tocilizumab by CTCAE grade

Category and terms	G0	G1	G2	G3	G4	G5
	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)
Any adverse event	**372 (59.2%)**	**45 (7.2%)**	**45 (7.2%)**	**55 (8.8%)**	**43 (6.8%)**	**68 (10.8%)**
Blood lymphatic category	**599 (95.4%)**	**8 (1.3%)**	**10 (1.6%)**	**9 (1.4%)**	**2 (0.3%)**	**0 (0.0%)**
anemia	617 (98.2%)	4 (0.6%)	2 (0.3%)	4 (0.6%)	1 (0.2%)	0 (0.0%)
Cardiac category	**605 (96.3%)**	**5 (0.8%)**	**7 (1.1%)**	**2 (0.3%)**	**3 (0.5%)**	**6 (1.0%)**
atrial fibrillation	625 (99.5%)	1 (0.2%)	1 (0.2%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
atrial flutter	627 (99.8%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
cardiac arrest	623 (99.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (0.8%)
myocardial infarction	627 (99.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	0 (0.0%)
cardiac disorders other	627 (99.8%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)	1 (0.2%)
Gastrointestinal category	**592 (94.3%)**	**13 (2.1%)**	**18 (2.9%)**	**3 (0.5%)**	**2 (0.3%)**	**0 (0.0%)**
diarrhea	611 (97.3%)	7 (1.1%)	8 (1.3%)	1 (0.2%)	1 (0.2%)	0 (0.0%)
mucositis oral	624 (99.4%)	1 (0.2%)	3 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
General category	**590 (93.9%)**	**14 (2.2%)**	**6 (1.0%)**	**4 (0.6%)**	**2 (0.3%)**	**12 (1.9%)**
fever	609 (97.0%)	13 (2.1%)	4 (0.6%)	1 (0.2%)	1 (0.2%)	0 (0.0%)
multi organ failure	616 (98.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	12 (1.9%)
Hepatobliary category	**627 (99.8%)**	**0 (0.0%)**	**0 (0.0%)**	**1 (0.2%)**	**0 (0.0%)**	**0 (0.0%)**
Immune system category	**625 (99.5%)**	**1 (0.2%)**	**1 (0.2%)**	**0 (0.0%)**	**1 (0.2%)**	**0 (0.0%)**
allergic reaction	625 (99.5%)	1 (0.2%)	1 (0.2%)	0 (0.0%)	1 (0.2%)	0 (0.0%)
Infections category	**597 (95.1%)**	**1 (0.2%)**	**8 (1.3%)**	**9 (1.4%)**	**5 (0.8%)**	**8 (1.3%)**
sepsis	623 (99.2%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	3 (0.5%)	1 (0.2%)
infection other	617 (98.2%)	0 (0.0%)	1 (0.2%)	2 (0.3%)	1 (0.2%)	7 (1.1%)
Investigations category	**519 (82.6%)**	**34 (5.4%)**	**27 (4.3%)**	**34 (5.4%)**	**14 (2.2%)**	**0 (0.0%)**
ALT	562 (89.5%)	25 (4.0%)	20 (3.2%)	19 (3.0%)	2 (0.3%)	0 (0.0%)
AST	571 (90.9%)	22 (3.5%)	18 (2.9%)	16 (2.5%)	1 (0.2%)	0 (0.0%)
bilirubine increased	621 (98.9%)	1 (0.2%)	2 (0.3%)	3 (0.5%)	1 (0.2%)	0 (0.0%)
creatinine increased	625 (99.5%)	1 (0.2%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	0 (0.0%)
lymphocyte count decreased	625 (99.5%)	1 (0.2%)	2 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
neutrophil count decreased	609 (97.0%)	3 (0.5%)	6 (1.0%)	7 (1.1%)	3 (0.5%)	0 (0.0%)
platelet count decreased	610 (97.1%)	2 (0.3%)	7 (1.1%)	6 (1.0%)	3 (0.5%)	0 (0.0%)
investigations other	625 (99.5%)	2 (0.3%)	0 (0.0%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
Metabolism category	**614 (97.8%)**	**6 (1.0%)**	**2 (0.3%)**	**3 (0.5%)**	**3 (0.5%)**	**0 (0.0%)**
Muscoloskeletal category	**626 (99.7%)**	**0 (0.0%)**	**1 (0.2%)**	**0 (0.0%)**	**0 (0.0%)**	**1 (0.2%)**
Nervous system category	**614 (97.8%)**	**4 (0.6%)**	**4 (0.6%)**	**4 (0.6%)**	**1 (0.2%)**	**1 (0.2%)**
intracranial hemorrhage	627 (99.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)
Renal category	**616 (98.1%)**	**3 (0.5%)**	**3 (0.5%)**	**3 (0.5%)**	**2 (0.3%)**	**1 (0.2%)**
acute kidney injury	624 (99.4%)	0 (0.0%)	0 (0.0%)	2 (0.3%)	1 (0.2%)	1 (0.2%)
Respiratory category	**535 (85.2%)**	**4 (0.6%)**	**13 (2.1%)**	**10 (1.6%)**	**31 (4.9%)**	**35 (5.6%)**
ARDS	619 (98.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	6 (1.0%)	3 (0.5%)
dyspnea	592 (94.3%)	3 (0.5%)	5 (0.8%)	9 (1.4%)	19 (3.0%)	0 (0.0%)
hypoxia	622 (99.0%)	0 (0.0%)	3 (0.5%)	2 (0.3%)	1 (0.2%)	0 (0.0%)

Category and terms	G0	G1	G2	G3	G4	G5
	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)
pneumonitis	624 (99.4%)	0 (0.0%)	0 (0.0%)	1 (0.2%)	3 (0.5%)	0 (0.0%)
pneumothorax	625 (99.5%)	1 (0.2%)	1 (0.2%)	1 (0.2%)	0 (0.0%)	0 (0.0%)
respiratory failure	585 (93.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	13 (2.1%)	30 (4.8%)
respiratory other	620 (98.7%)	1 (0.2%)	0 (0.0%)	4 (0.6%)	1 (0.2%)	2 (0.3%)
Vascular category	**606 (96.5%)**	**1 (0.2%)**	**3 (0.5%)**	**10 (1.6%)**	**4 (0.6%)**	**4 (0.6%)**
hypertension	615 (97.9%)	1 (0.2%)	3 (0.5%)	7 (1.1%)	2 (0.3%)	0 (0.0%)
thromboembolic event	621 (98.9%)	0 (0.0%)	0 (0.0%)	3 (0.5%)	1 (0.2%)	3 (0.5%)
vascular disorder other	627 (99.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.2%)

Table A7. Multivariable logistic regression

(patients receiving tocilizumab more than three days after registration are excluded)

	14 days (143 events/1002 patients)			30 days (191 events/980 patients)		
	Beta coefficient	**OR of death (95% CI)**	**P**	**Beta coefficient**	**OR of death (95% CI)**	**P**
Age			<0.001			<0.001
≤60		Reference			Reference	
61-70		2.82 (1.55-5.14)			2.32 (1.42-3.80)	
70+		12.15 (6.91-21.37)			9.62 (6.00-15.42)	
Gender			0.39			0.25
Female		Reference			Reference	
Male		1.24 (0.76-2.02)			1.30 (0.83-2.04)	
PaO2/FiO2 ratio			0.02			<0.001
≤100		Reference			Reference	
101-200		0.51 (0.27-0.94)			0.50 (0.29-0.86)	
>200		0.35 (0.15-0.80)			0.24 (0.11-0.51)	
Missing or not assessed		0.87 (0.50-1.49)			0.75 (0.46-1.23)	
Geographic area			0.28			0.37
Lombardia		Reference			Reference	
Emilia Romagna		0.55 (0.26-1.20)			0.68 (0.34-1.35)	
Veneto		1.04 (0.56-1.90)			1.18 (0.69-2.02)	
Other Northen Regions		0.88 (0.40-1.94)			0.64 (0.30-1.36)	
Centre		0.55 (0.30-1.01)			0.69 (0.40-1.18)	
South and Islands		0.60 (0.27-1.32)			0.71 (0.36-1.42)	
Population			0.002			0.16
Phase 2		Reference			Reference	
Validation		0.49 (0.31-0.77)			0.74 (0.49-1.12)	
Treatment			0.003			0.015
Not administered	Reference			Reference		
Administered	1.047			-0.747		
Respiratory support			0.97			0.023
Oxygen	Reference			Reference		
NIMV	0.061			0.176		
IMV	0.085			1.168		
Treatment*Respiratory support			0.02			0.045
Oxygen	Reference			Reference		
NIMV	1.152			1.035		
IMV	1.449			0.704		

Figure A3. Relative (Odds Ratio of death, panel A) and absolute (difference in lethality rate, panel B) measures of treatment effect by required respiratory support at 14 and 30 days.



List of participating centers and Co-Investigators

TOCIVID-19 Investigators

- Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli - Clinical Trials Unit: Francesco Perrone, Maria Carmela Piccirillo, Clorinda Schettino, Adriano Gravina, Piera Gargiulo, Claudia Cardone, Laura Arenare; Melanoma And Cancer Immunotherapy And Developmental Therapeutics Unit: Paolo Antonio Ascierto, Maria Grazia Vitale, Claudia Trojaniello, Marco Palla; Direction: Attilio Antonio Montano Bianchi, Gerardo Botti, Gianfranco De Feo, Leonardo Miscio.
- Università degli Studi della Campania Luigi Vanvitelli, Dipartimento di Salute Mentale e Medicina Preventiva; Ciro Gallo, Paolo Chiodini.
- IRCCS Policlinico San Donato - Milano: Laurenzia Ferraris, Massimiliano M. Marrocco-Trischitta, Marco Froldi, Lorenzo Menicanti, Maria Teresa Cuppone, Giulia Gobbo, Chiara Baldessari, Vincenzo Valenti, Serenella Castelvecchio, Federica Poli, Francesca Giacomazzi, Rosangela Piccinni, Maria Laura Annnunziata, Andrea Biondi, Cecilia Bussolari, Manuel Mazzoleni, Andrea Giachi, Annalisa Filtz, Arianna Manini, Enrico Poletti, Federico Masserini, Francesco Conforti, Gianfranco Gaudiano, Vittoria Favero, Alice Moroni, Tommaso Viva, Fabiana Fancoli, Davide Ferrari, Dario Niro, Marco Resta, Andrea Ballotta, Marco Dei Poli, Marco Ranucci.
- ASST Papa Giovanni XXIII – Bergamo: Diego Ripamonti, Francesca Binda, Alessandra Tebaldi, Giuseppe Gritti, Luisa Pasulo, Leonardo Gaglio, Roberto Del Fabbro, Leonardo Alborghetti.
- ASST Monza – Monza: Paolo Bonfanti, Nicola Squillace, Giulia Giustinetti, Paola Columpsi, Marina Cazzaniga, Serena Capici, Luca Sala, Riccardo Di Sciacca, Giacomo Mosca, Maria Rosa Pirozzi.
- ASST degli Spedali Civili di Brescia e Università di Brescia - Brescia: Francesco Castelli, Maria Lorenza Muiesan, Franco Franceschini, Aldo Roccaro, Massimo Salvetti, Anna Paini, Luciano Corda, Chiara Ricci, Lina Tomasoni, Paola Nasta, Silvia Lorenzotti, Silvia Odolini, Emanuele Focà, Eugenia Quiros Roldan, Marco Metra, Stefano Magrini, Paolo Borghetti, Nicola Latronico, Simone Piva, Matteo Filippini, Gabriele Tomasoni, Francesco Zuccalà, Sergio Cattaneo, Francesco Scolari, Nicola Bossini, Mario Gaggiotti, Martina Properzi.
- Ospedale Santa Maria Goretti – Latina: Miriam Lichtner, Emanuela Del Giudice, Raffaella Marocco, Anna Carraro, Cosmo Del Borgo, Raffaella Marocco, Valeria Belvisi, Tiziana Tieghi, Margherita De Masi, Paola Zuccalà, Paolo Fabietti, Angelo Vetica, Vito Sante Mercurio, Anna Carraro, Laura Fondaco, Blerta Kertusha, Ambrogio Curtolo, Emanuela Del Giudice, Riccardo Lubrano, Maria Gioconda Zotti, Antonella Puorto, Marcello Ciuffreda, Antonella Sarni, Gabriella Monteforte, Domenico Romeo, Emanuela Viola, Carla Damiani, Antonietta Barone, Barbara Mantovani, Daniela Di Sanzo, Vincenzo Gentili, Massimo Carletti, Massimo Aiuti, Andrea Gallo, Piero Giuseppe Meliante, Salvatore Martellucci, Oliviero Riggio, Vincenzo Cardinale, Lorenzo Ridola, Maria Consiglia Bragazzi, Stefania Gioia, Emiliano Valenzi, Camilla Graziosi, Niccolò Bina, Martina Fasolo, Silvano Ricci, Maria Teresa Gioacchini, Antonella Lucci, Luisella Corso, Daniela Tornese, Parni Nijhawan, Francesco Equitani, Carmine Cosentino, Marcello Palladino, Frida Leonetti, Gaetano Leto, Camillo Gnessi, Giuseppe Campagna, Roberto Cesareo, Francesca Marrocco, Giuseppe Straface, Alessandra Mecozzi, Lidia Cerbo, Valentina Isgrò, Sergio Parrocchia, Giuseppe Visconti, Giorgio Casati.
- AOU di Parma - Parma: Carlo Calzetti, Alarico Ariani, Lorenzo Donghi.
- AOUI di Verona - Verona: Nicola Duccio Salerno, Evelina Tacconelli, Marco Bertoldi, Paolo Cattaneo, Lorenza Lambertenghi, Leonardo Motta, Luca Omega.
- Humanitas Gavazzeni – Bergamo: Giovanni Albano.
- AORN Dei Colli – Napoli: Roberto Parrella, Fiorentino Fraganza, Luigi Atripaldi, Vincenzo Montesarchio, Francesco Scarano, Annunziata De Rosa, Amalia Buglione, Sabrina Lavoretano, Gianfranco Gaglione, Mario De Marco, Vincenzo Sangiovanni, Francesco Maria Fusco, Rosaria Viglietti, Elio Manzillo, Carolina Rescigno, Raffaella Pisapia, Giulia Plamieri, Alberto Maraolo, Giosuè Calabria, Mario Catalano, Giuseppe Fiorentino, Anna Annunziata, Giorgio Polistina, Pasquale Imitazione, Mariano Mollica, Vincenzo Esposito, Maurizio D'Abraccio, Rodolfo Punzi, Vincenzo Bianco, Costanza Sbreglia.
- Azienda Ospedaliera Umberto I – Siracusa: Rosa Fontana Del Vecchio, Alessandro Bordonali, Antonina Franco.
- Arcispedale Santa Maria Nuova IRCCS - Reggio Emilia: Carlo Salvarani, Marco Massari, Giovanni Dolci, Pierpaolo Salsi, Matteo Fontana.
- ASST di Cremona - Cremona: Giuseppe Virzì, Calderone Ornella, Alfredo Molteni.
- Azienda Ospedaliera San Salvatore – Pesaro: Silvia Gennarini, Umberto Gnudi, Maria Anastasia Ricci, Giancarlo Titolo, Giulio Mensi, Pietro Vuotto, Beatrice Gasperini, Mauro Mancini, Zeno Pasquini.
- Ospedale Bassini - Cinisello Balsamo: Paolo Spanu, Stefano Clementi, Simona Pierini, Daniela Bokor, Daniela Gori, Morena Ciofetti, Marina Caimi, Laura Bettazzi, Elisabetta Allevi, Silvia Furiani, Chiara Capitanio,

Bernardino Mastropasqua, Claudio Fara, Grazia Pulitanò, Jun Sebastian Matsuno, Francesca Della Porta, Viola Dolfini, Nebiat Balei Beyene.

- ASST Degli Spedali Civili Di Brescia - Brescia: Michela Bezzi, Mauro Novali.
- AOU di Bologna - Bologna: Pierluigi Viale, Sara Tedeschi, Renato Pascale.
- Policlinico S. Matteo - Pavia: Raffaele Bruno, Alessandro Di Filippo, Michele Sachs, Tiberio Oggionni, Michele Di Stefano, Caterina Mengoli.
- Ospedale di Conegliano - Conegliano: Cesarina Facchini, De Nardo Daniele.
- Azienda Ospedaliera San Salvatore – Pesaro: Gabriele Frausini, Luciano Mucci, Silvia Tedesco, Rita Girolimetti, Elena Manfredini, Anna Maria Di Carlo, Emma Espinosa, Donatella Dennetta.
- AOU di Parma - Parma: Andrea Ticinesi, Tiziana Meschi, Antonio Nouvenne.
- Azienda Ospedaliera Ordine Mauriziano – Torino: Norbiato Claudio, Francesco Vitale, Marta Saracco.
- Ospedale Guglielmo Da Saliceto – Piacenza: Mauro Codeluppi, Elisa Fronti, Patrizia Ferrante.
- Ospedale di Fermo - Fermo: Giorgio Amadio Nespola.
- AOU di Perugia - Perugia: Daniela Francisci, Andrea Tosti.
- Casa Sollievo Della Sofferenza - San Giovanni Rotondo: Cristiano Matteo Carbonelli, Antonio Greco, Maria Giulia Tinti.
- Fondazione Poliambulanza Istituto Ospedaliero – Brescia: Roberto Stellini, Camilla Appiani, Piera Reghenzi.
- Ospedale Morgagni-Pierantoni - Forlì: Venerino Poletti, Claudia Ravaglia.
- Ospedale Area Aretina Nord - Arezzo: Danilo Tacconi, Costanza Malcontenti.
- AO Novara e Galliate - Novara: Mario Pirisi, Pier Paolo Sainaghi.
- Policlinico Umberto I – Roma: Claudio Maria Mastroianni, Gianluca Russo.
- Presidio Ospedaliero di Jesolo - Jesolo: Toffoletto Fabio, Francesco Saverio Serino, Lucio Brollo, Elena Momesso, Maria Luisa Turati.
- ASST Santi Paolo e Carlo – Milano: Antonella D'arminio Monforte, Giulia Marchetti.
- Ospedale Civile di Guastalla - Guastalla: Fabrizio Boni, Elisabetta Teopompi, Chiara Trenti, Luca Boracchia, Enrica Minelli, Matteo Fontana, Giulia Ghidoni, Anaflorina Matei, Andrea Caruso.
- AO Ospedali Riuniti Villa Sofia e Cervello – Palermo: Giuseppe Arcoleo, Gaetana Camarda, Filippo Catalano, Mario Spatafora.
- Ospedale Sacra Famiglia, Fatebenefratelli – Erba: Donato Bettega.
- AOU Policlinico Tor Vergata – Roma: Massimo Andreoni, Elisabetta Teti, Loredana Sarmati, Andrea Di Lorenzo, Mariagrazia Celeste.
- Ospedali Riuniti Padova Sud - Padova: Fabio Baratto, Jacopo Monticelli, Pietro Criveller.
- Ospedale San Paolo – Savona: Antonini Andrea, Anselmo, Riccio.
- ASST Spedali Civili Di Brescia - Brescia: Maurizio Castellano, Carlo Cappelli, Federica Corvini, Barbara Zanini.
- ASST Spedali Civili Di Brescia, Presidio Ospedaliero Gardone – Brescia: Massimo Crippa, Maurizio Ronconi, Raffaella Costa, Silvia Casella, Loretta Brentana.
- Ospedale Civile e Ospedale Dell'Angelo - Mestre: Livio Bernardi, Andrea Frascati, Sandro Panese, Fabio Presotto, Lucio Michieletto, Cristina Bernardi.
- Ospedale Santa Maria Delle Croci – Ravenna: Maurizio Fusar.
- Presidio Ospedaliero di Cesena - Cesena: Vanni Agnoletti, Martina Farina, Russo.
- AOU Careggi – Firenze: Federico Lavorini, Roberta Ginanni.
- Istituto Nazionale Malattie Infettive INMI L. Spallanzani, IRCCS – Roma: Fabrizio Palmieri, Silvia Mosti.
- Casa Di Cura Beato Palazzolo – Bergamo: Angelo Amaglio, Alessandra Cattaneo.
- Istituto Clinico S. Ambrogio Spa – Milano: Silvia Cirri, Andrea Montisci, Chiara Gallazzi, Daniele Cosseta, Barabara Baronio, Lorenzo Rampa.
- AO Sant'Anna e San Sebastiano – Caserta: Paolo Maggi, Vincenzo Messina.
- Arcispedale Santa Maria Nuova IRCCS - Reggio Emilia: Emanuele Alberto Negri, Chiara Trenti.
- Ospedale Generale Provinciale – Macerata: Marialma Berlendis, Maria Cecilia Sabatti.
- Azienda Ospedaliera S.Maria - Terni: Michele Palumbo.
- ASST Ovest Milanese – Milano: Antonino Mazzone, Paola Faggioli.
- Ospedale Bellaria – Bologna: Linda Bussini, Giacomo Fornaro, Francesca Volpato.
- Ospedale Maria Vittoria – Torino: Daniele Imperiale, Emilpaolo Manno, Enrico Ferreri, Domenico Martelli, Andrea Verhovez, Silvia Giorgis, Luciana Faccio, Rachele Delli Quadri, Cristina Negro.
- Ospedale Giovanni Bosco – Torino: Marcella Converso, Francesca Bosco.
- ASST Desenzano Del Garda – Gavardo: Silvia Amadasi, Paolo Prandini, Silvia Cocchi.
- Azienda ULSS 6 – Vicenza: Vinicio Manfrin, Veronica Del Punta.
- PO Sant'Elia – Caltanissetta: Giovanni Mazzola, Giuseppe Sportato.

- Ospedale Ca' Foncello – Treviso: Micaela Romagnoli.
- Ospedale Infermi - Rimini: Francesco Cristini, Francesca Facondini, Tiziana Perin, Andrea Boschi.
- AOU di Modena - Modena: Cristina Mussini, Marianna Meschiari, Giovanni Guaraldi.
- Presidio Ospedaliero San Luca – Lucca: Sara Modica, Sara Moneta, Daniela Boccalatte, Clara Ricci, Valentina Marchetti.
- ASST Desenzano Del Garda - Ospedale Di Manerbio: Silvia Amadasi, Gabriele Ebbreo, Michael Dalè, Paolo Tura.
- AO Spedali Civili, PO Montichiari – Brescia: Damiano Rizzoni, Gianluca Edoardo Mario Boari, Silvia Bonetti.
- Ospedale San Liberatore di Atri - Teramo: Enrico Marini, Italiani Daniele.
- ASST Dei Sette Laghi – Varese: Paolo Antonio Grossi, Nichola Walter Delfrate.
- Ospedale Aziendale Di Bressanone - Bressanone: Othmar Bernhart, Gilbert Spizzo, Klaus Mahlknecht, Thomas Volkl.
- Ospedale San Jacopo - USL Toscana Centro - Pistoia: Massimo Antonio Di Pietro, Michele Trezzi, Cecilia Monacci.
- Ospedale di Rovigo - Rovigo: Adriano Peris, Manuela Bonizzoli.
- Ospedale Guglielmo Da Saliceto – Piacenza: Luigi Cavanna, Carlo Moroni, Elisa Maria Stroppa, Alessandra Manini.
- ASST Garda - Ospedale Civile La Memoria - Gavardo: Maria Cristina Savio, Francesca Gatti, Clara Bartolaminelli.
- Istituto Nazionale Malattie Infettive INMI L. Spallanzani, IRCCS – Roma: Nicola Petrosillo, Davide R. Donno, Fabrizio Taglietti, Simone Topino, Pierangelo Chinello, Vincenzo Galati.
- Istituto Nazionale Malattie Infettive INMI L. Spallanzani, IRCCS – Roma: Gianpiero D'offizi, Chiara Taibi.
- Ospedale Fiorentino – Firenze: Barbara Cimolato, Federico Moroni, Nicolas Palagano, Lorenzo Pelagatti, Seravalle Cristiana, Giancarlo Landini.
- Azienda Ospedaliera S. G. Moscati – Avellino: Maria Amitrano, Mariangela Raimondo, Sara Mangiacapra, Annamaria Romano, Mariangela Atteno.
- Ospedale S.M. Annunziata - AUSL Toscana Centro - Grassina: Pierluigi Blanc, Lorenzo Roberto Suardi, Carlo Pallotto
- Ospedale F. Spaziani – Frosinone: Katia Casinelli, Ilaria Uccella.
- Ospedale S. Giuseppe – Milano: Sergio Harari, Antonella Caminati.
- Ospedale Amedeo Di Savoia – Torino: Filippo Lipani, Giovanni Di Perri, Andrea Calcagno, Guido Calleri, Chiara Montrucchio, Anna Maria Caputo.
- Presidio Ospedaliero S.Maria Del Carmine –Rovereto: Susanna Cozzio, Livia Delle Donne.
- AO Policlinico Ospedale S. Martino – Genova: Matteo Bassetti, Mikulska Malgorzata, Laura Ambra Nicolini, Chiara Russo, Chiara Sepulcri, Sabrina Beltramini, Federica Mina.
- ASST Grande Ospedale Metropolitano Niguarda – Milano: Massimo Puoti, Anna Gandino, Thomas Langer, Federico D'amico.
- ASST Spedali Civili Di Brescia - Brescia: Marialma Berlendis, Chiara Rocchetti, Francesca Cettolo.
- Presidio Ospedaliero Aziendale, AUSL Parma - Parma: Frausini Gabriele, Pietro Bocchi.
- Ospedale Pavullo nel Frignano – Modena: Giorgio Cioni, Cinzia Cappi.
- AOU Città della Salute e della Scienza - Ospedale Le Molinette – Torino: Silvia Corcione, Francesco Giuseppe De Rosa, Silvia Scabini, Francesca Canta, Simone Mornese Pinna, Anna Pensa.
- Ospedale San Giuseppe - AUSL Toscana Centro - Empoli: Pierluigi Blanc, Lorenzo Roberto Suardi, Carlo Pallotto.
- Azienda Ospedaliera Sant'Andrea – Roma: Monica Rocco, Maria Teresa Cirasa.
- AOU Careggi – Firenze: Michele Spinicci, Jessica Mencarini, Lorenzo Zammarchi.
- Presidio Ospedaliero Unificato - San Remo: Cenderello Giovanni, Katiuscia Sciolè.
- Presidio Ospedaliero Santa Maria della Misericordia – Udine: Flavio Bassi.
- Casa Di Cura S. Rita – Milano: Michele Bianchi, Sillia Frigerio.
- Ospedale F. Spaziani – Frosinone: Sandra Spaziani, Antonia Nucera.
- AO Luigi Sacco - Milano: Giuliano Rizzardini, Maria Vittoria Cossu, Marco Antivalle.
- AOU Policlinico Vittorio Emanuele – Catania: Giuseppe Carpinteri.
- Presidio Ospedaliero Riuniti - Reggio Calabria: Sebastiano Macheda, Demetrio Labate.
- ASST Grande Ospedale Metropolitano Niguarda – Milano: Maurizio Bottiroli.
- Ospedale V. Fazzi - Lecce: Anacleto Romano.
- Ospedale Generale Regionale – Bolzano: Elke Maria Erne, Zocchetti Cristina.
- Ospedale Mazzini – Teramo: Valeria Di Biase.

- ASST di Cremona - Cremona: Fabio Malberti, Alfredo Molteni.
- ASST degli Spedali Civili di Brescia - Brescia: Giovanni Montani, Paolo Poisa, Daniela Bettini.
- Policlinico Universitario A. Gemelli – Roma: Roberto Cauda, Arturo Ciccullo.
- Ospedale Sacro Cuore Don Calabria - Negrar (Verona): Niccolò Riccardi, Andrea Angheben.
- Ospedale Valduce Dous – Como: Mauro Turrini, Raffaella Clerici, Angelo Gardellini, Luigi Liparulo, Tizana Rossini.
- PO SS. Annunziata – Chieti: Claudio Ucciferri, Francesco Cipollone, Jacopo Vecchiet.
- Ospedale S.G. Moscati – ASL Taranto - Taranto: Andrea Nico, Lorenzo Marra, Armando Leone, Antonia Sdanganelli, Giuseppe Antonio Palmiotti, Giancarlo D'Alagni.
- AOU Opsedali Riuniti – Foggia: Teresa Antonia Santantonio, Sergio Lo Caputo, Irene Bottalico.
- AO Sant'Anna e San Sebastiano – Caserta: Antonio Ponticiello, Felicia Di Perna.
- Ospedale Ca' Foncello – Treviso: Enrico Bernardi, Angela Beltrame, Stefania Bravi, Marco David, Paola Bernardi.
- Ospedale G.Tatarella - Cerignola (Foggia): Dario Galante.
- ASST Franciacorta - Presidio Ospedaliero di Iseo: Maria Cristina Uccelli, Katiela Prestini, Monica Drera, Enea Zini, Alessio Peregrinelli, Laura Blanzuoli.
- Ospedale di Mondovì - ASL CN1 – Cuneo: Valentina Benedetti, Rovberta Calvi, Nadia Scaglione, Gabriella Nallino.
- IRCCS Istituto Ortopedico Galeazzi Spa – Milano: Maurizio Bonazzi, Tiziano Crespi, Tiziana Masolin.
- Ospedale Delmati - Sant Angelo Lodigiano: Angelo Regazzetti, Maria Chiara Cerri, Elena Maffezzini, Manuela Piazza, Claudia Papetti, Claudia De Filippi, Elena Roveda, Giuseppe Cipolla, Mariano Scozzafava, Monica Crepaldi, Sonia Henchi, Nicolò Vanoni, Alice Repossi, Monia Vezzoli, Eva Scorletti, Orietta Perugini, Simone Marino Pasini, Veronica Pacetti, Luisella Ferrari, Giovanna Attilia de Paduanis, Sara del Duca, Francesca dell'Ara, Alessandra Brocchieri, Guja Minoja, Enrico Storti, Loredana Pitagora, Isabella Costa, Fanny Delfanti, Matteo Orlandi.
- AO Ospedale Niguarda Ca Granda – Milano: Ruggero Ruggeri, Lorenzoa Ruggieri.
- AO S. Giovanni Bosco – Torino: Sergio Livigni, Daniela Silengo.
- AO Ospedale di Circolo e Fondazione Macchi – Varese: Walter Ageno.
- Ospedale Bolognini – Seriate: Luciano Pedrini.
- Ospedale Sant'Andrea - La Spezia: Stefania Artiol.
- Ospedale Di Senigallia - Senigallia: Laura Morbidoni.
- ASST di Mantova - Mantova: Giuseppe De Donno, Viviana Ravagnani, Francesco Inglese.
- Ospedale Ca' Foncello – Treviso: Pier Giorgio Scotton.
- Ospedale Civile Di Saluzzo – ASL CN1 – Cuneo: Paolo Costantini, Maurizio Delucchi.
- AOU di Modena - Modena: Enrico Clini.
- Ospedale Di Senigallia - Senigallia: Andrea Ansuini.
- Ospedale San Bassiano - Bassano Del Grappa: Baiocchi Marco, Lain Giuseppe.
- Presidio Ospedaliero Aziendale AUSL Parma – Fidenza: Brianti Vincenzo, Gianni Rastelli.
- AOU di Padova - Padova: Andrea Doria, Andrea Vianello, Anna Maria Cattelan, Sara Bindoli, Mara Felicietti.
- ASST di Crema - Crema: Ciro Canetta, Alessandro Scartabellati, Silvia Accordino.
- PO Sant'Ottone Frangipane - Ariano Irpino: Maurizio Ferrara, Livio Cocco, Fernanda Cirillo, Erminio Pace, Monica De Caro, Marielisa Alberico, Giovanni Benigni, Terenzio Damiano, Pierluigi Fusco, Angela Iuorio, Giacomo Torretta.
- Ospedale S. Carlo Borromeo – Milano: Milena Racagni, Stefano Muttini.
- ASST della Valle Olona – Busto Arsizio: Girolamo Sala, Paolo Ghiringhelli.
- PO Maria SS. Addolorata – Eboli: Fernando Chiumiento, Laura Baccari.
- Arcispedale Santa Maria Nuova - Reggio Emilia: Enrica Minelli, Boracchia Luca, Federica Bocchi, Francesco Benatti, Jacopo Catellani.
- Ospedale di Belluno - Belluno: Marina Coppola.
- AOU di Ferrara - Ferrara: Alberto Papi.
- Ospedale di Conegliano - Conegliano: Enrico Bosco.
- AO Universitaria Careggi – Firenze: Mnuela Bonizzoli, Chiara Lazzeri.
- Ospedale Della Misericordia - Grosseto: Nencioni Cesira, Camilla Puttini, Tiziana Carli, Leonardo Croci, Marta Corridi.
- Ospedale di Stato di San Marino: Massimo Arlotti, Giulio Guerrini.
- Presidio Ospedaliero Unico AV4 - Fermo: Luisanna Cola, Michela Romanelli.
- AOU Ospedali Riuniti – Ancona: Marina Bonifazi, Stefano Gasparini, Federico Mei, Elisabetta Cerutti.
- AO Ospedali Riuniti - Foggia: Donato Lacedonia.

- Istituto Clinico Humanitas – Rozzano: Armando Santoro, Giacomo Maria Guidelli.
- Ospedale Generale Provinciale – Saronno: Stefano Greco, Andrea Castellan, Gessica Infantino, Laura Camici.
- Ospedale S. M. Annunziata, AUSL Toscana Centro - Grassina: Francesca Covani Frigieri, Vittorio Pavoni
- AOU Senese - Siena: Lucia Migliori, Barbara Rossetti, Francesca Montagnini.
- PO Mauro Scarlato – Scafati: Immacolata Mauro, Elvira Genovese, Antonio Capuozzo, Leonarda Vitiello, Emanuele Sirignano.
- ASST della Franciacorta - Chiari: Paolo Gnesin.
- AOU Federico II – Napoli: Giuseppe Servillo, Alfredo Marinelli.
- AOU di Sassari - Sassari: Daniela Pasero, Lorenzo Casadio, Sergio Babudieri, Giordano Madeddu, Andrea De Vito, Lorenzo Casadio, Melania Ranghitta.
- ASST di Cremona - Cremona: Rodolfo Passalacqua, Fioravanti Antonio, Alfredo Molteni.
- AOU Federico II –Napoli: Ivan Gentile, Antonio Riccardo Buonomo, Riccardo Scotto, Emanuela Zappulo.
- AO S. G. Moscati – Avellino: Giuseppina Dell'Aquila.
- Istituto Clinico S.Anna – Brescia: Angel Bianchetti, Fabio Guerini.
- PO Jazzolino - Vibo Valentia: Alfredo Vallone, Peppino Oppedisano.
- Ospedale Teresa Masselli Mascia Di San Severo - Foggia: Dario Galante.
- Ospedale S. Anna – Como: Luigi Pusterla, Omar Giglio.
- P.O. Maria SS. Addolorata – Eboli: Grazia Russo.
- ASST degli Spedali Civili Di Brescia - Brescia: Enrico Sartori, Cristina Zanardini.
- Ospedale Sen. A. Perrino – Brindisi: Pietro Gatti, Valiani Vincenzo.
- Ospedale Amedeo Di Savoia – Torino: Guido Calleri.
- ASST di Lecco – Lecco: Stefania Piconi, Chiara Molteni.
- ASST di Bergamo Ovest - Bergamo-Treviglio: Giuseppina Dognini.
- Ospedale Castel San Giovanni, Covid Hospital - Piacenza-Castel San Giovanni: Franco Cosimo.
- PO Umberto I - Enna: Luigi Guarneri, Fabrizio Pulvirenti.
- Stabilimento Ospedaliero Castelli – Verbania: Vincenzo Mondino, Gabriella Traballi.
- Ospedale Fatebenefratelli E Oftalmico – Milano: Enrico Iemoli, Antoenlla Grisolia, Riccardo Giorgi, Gabriella Nucera, Valentina Raffaelli, Pietro Marino, Enrica Negro, Lisa Serati, Tamanini Silvia
- AO per l'Emergenza Cannizzaro – Catania: Carmelo Iacobello, Giuseppe Strano.
- Ospedale Sant'Andrea – Vercelli: Lucio Boglione.
- Ospedale Regionale Umberto Parini – Aosta: Alberto Catania, Paola Gipponi.
- AO S.Maria – Terni: Luca Di Cato, Anna Panaccione.
- Policlinico San Marco – Zingonia: Giovanni Vitale, Ilaria Alice Crippa, Matteo Giacomini.
- AO Niguarda Ca Granda – Milano: Adriano Basile, Bellone Andrea.
- Ospedale di Galatina S.Caterina Novella - Galatina: Paolo Tundo.
- Ospedale Versilia – Camaiore: Stefano Buzzigoli, Gerardo Palmiero.
- Ospedale Guglielmo Da Saliceto – Piacenza: Andrea Magnaca, Matteo Silva.
- ASST Lecco – Merate: Massimo Ricci, Stefano Crespi, Bernadetta Pasquino.
- Nuovo Ospedale Di Prato S. Stefano – Prato: Guglielmo Consales.
- Casa Di Cura Privata - Peschiera Del Garda: Damiano Bragantini.
- Ospedale Generale Regionale Miulli, Covid Hospital, Acquaviva Delle Fonti – Bari: Franco Mastroianni, Giulia Righetti, Antonio Scafarino, Michele Bitetto.
- ASST della Valle Olona - Busto Arsizio: Fabio Franzetti.
- Ospedale SS. Trinità – Cagliari: Sandro Piga.
- Ospedale Generale Regionale Miulli, Acquaviva Delle Fonti – Bari: Vito Delmonte
- Ospedale Bisceglie – Bisceglie: Sergio Carbonara, Ruggero Losappio.
- Ospedale Aziendale Di Brunico – Brunico: Christian Dejaco
- Policlinico Umberto I – Roma: Claudio Mastroianni, Gianluca Russo.
- AO S. Croce e Carle – Cuneo: Valerio Del Bono.
- Ospedale Santa Maria Bianca – Mirandola: Fabio Gilioli.
- Ospedale Di Mirano – Mirano: Daniela Barzan, Silvia De Struppi.
- Ospedale Alto Vicentino – Santorso: Antonio Carlotto, Maria Licia Guadagnin.
- AOU di Modena – Modena: Massimo Girardis, Elisabetta Bertellini.
- ASST dei Sette Laghi – Varese: Francesco Dentali.
- PO Sant'Elia – Caltanissetta: Giancarlo Foresta.
- Ospedale Apuane – Massa: Alberto Baratta, Rosangela Viviani.
- ASST Grande Ospedale Metropolitano Niguarda – Milano: Antonio Maria Agrati.
- Istituto Auxologico Italiano - I.S. S.Luca – Milano: Giovanni Battista Perego.

- AOU Policlinico - Vittorio Emanuele – Catania: Arturo Montineri, Rosa Manuele.
- AO Gravina e S. Pietro – Caltagirone: Salvatore Bonfante.
- Nuovo Ospedale Di Prato S. Stefano – Prato: Donatella Aquilini.
- Complesso Ospedaliero A. Cardarelli - Campobasso: Alessandra Prozzo, Donato Santopuoli, Zaira Di Rosa.
- Policlinico San Pietro - Ponte San Pietro: Armando Alborghetti, Paolo Peci, Nikoloz Bakhtadze, Chiara Stefania Pandini, Giovanni Casati, Najat Ashofarir.
- AO Ospedale Niguarda Ca' Granda - Milano: Giampaolo Casella
- Ospedale Di Trento – Trento: Walter Spagnolli, Silvana Urru, Ivan Marchesoni, Giulia Caminiti
- Istituto Clinica Città di Brescia – Brescia: Elena Argilloni, Elisabetta Danieli, Gianluca Ghirardi, Chiara Maria Antonioli, Alessio Lipari, Paola Zavarise, Francesco Kokaly.
- AOUI Verona Borgo Trento – Verona: Enrico Polati, Leonardo Gottin
- Presidio Ospedaliero Di Vittorio Veneto - Vittorio Veneto: Paolo Lucernoni, Fabio De Conti, Elisabetta Marcon.
- Ente Ospedaliero Ospedali Galliera – Genova: Emanuele Pontali, Elisabetta Blasi Vacca, Carolina Saffioti, Alessia Zunino.
- AOU Ospedali Riuniti di Trieste – Trieste: Erik Roman Pognuz, Giorgio Berlot.
- Ospedale Moscati - Taranto/Statte: Martino Saltori.
- Ospedale Di San Bonifacio - San Bonifacio (VR): Andrea Tedesco.
- ASST del Garda – Desenzano: Silvia Amadasi.
- Ospedale di Treviso –Treviso: Carlo Agostini.
- Ospedale Maggiore – Modica: Maria Antonietta Di Rosolini, Francesco Marino.
- Istituto di Cura Città Di Pavia – Pavia: Guido Bellinzona.
- Ospedale Carlo Urbani Di Jesi – Jesi: Walter Grassi, Marco Di Carlo.
- Ospedale Maggiore Modica – Modica: Guglielmo Scimonello.
- ASST Grande Ospedale Metropolitano Niguarda – Milano: Sandra Nonini, Michele Mondino.
- Villa Maria Cecilia Hospital - Cotignola (RA): Lorenzo Filippo Mantovani, Elena Tenti.
- ARNAS Garibaldi – Catania: Concetta Maria Gabriella Tropea, Daniela Emanuela Di Stefano.
- Ospedale Privato Villalba Hospital: Paolo Guelfi.
- IRCCS S. Raffaele – Milano: Lorenzo Dagna.
- PO Gravina e S. Pietro – Caltagirone: Gianfranco Morgana.
- ASST Grande Ospedale Metropolitano Niguarda – Milano: Lidia Montemurro.
- AOUI Verona - Borgo Roma – Verona: Domenico Girelli, Ernesto Crisafulli, Alessio Maroccia.
- ASST Grande Ospedale Metropolitano Niguarda – Milano: Alessandra Maria Cemuschi.
- Ospedale Gagliardi – Trecenta: Mara Bernasconi.
- Ospedale Maggiore SS. Annunziata – Savigliano: Ugo Zummo.

TOCIVID-19 Study Coordinators

- Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli - Clinical Trials Unit: Valentina Barbato, Simona Bevilacqua, Gaetano Buonfanti, Giuliana Canzanella, Giovanni De Matteis, Manuela Florio, Marilena Martino, Maria Teresa Ribecco, Fiorella Romano, Alfonso Savio, Lucia Sparavigna: Melanoma And Cancer Immunotherapy And Developmental Therapeutics Unit: Marcello Curvietto.
- IRCCS Policlinico San Donato – Milano: Michele Citarella.
- ASST Papa Giovanni XXIII – Bergamo: Leonardo Alborghetti.
- Humanitas Gavazzeni – Bergamo: Valeria Nava, Paola Maggioni, Marta Magni.
- AORN Dei Colli – Napoli: Chiara Iommelli, Antonella Bianco.
- Arcispedale Santa Maria Nuova IRCCS Di Reggio Emilia: Romina Corsini, Linda Valli, Maria Paola Ruggieri.
- ASST di Cremona - Cremona: Annalisa Mancini.
- Azienda Ospedaliera San Salvatore – Pesaro: Tiziana Melica.
- Policlinico S. Matteo – Pavia: Alessandra Ferrari, Daniela Cicognini, Mariangela Delliponti, Andrea Zuccarini, Silvia Ciani.
- AOU di Parma - Parma: Davide Raffaeli
- Ospedale Morgagni Pierantoni – Forlì: Luca Donati.
- ASST Santi Paolo e Carlo – Milano: Stefania Cannizzo.
- Ospedale Civile Guastalla – Guastalla: Stefania Lui.
- Arcispedale Santa Maria Nuova IRCCS di Reggio Emilia – Reggio Emilia: Romina Corsini, Linda Valli, Maria Paola Ruggieri.
- Ospedale Infermi Rimini: Luca Santini.
- AOU di Modena – Modena: Enrica Roncaglia, Pasquale Mighali.

- Ospedale Aziendale Di Bressanone – Bressanone: Frederik Eisendle.
- Ospedale San Jacopo – USL Toscana Centro: Giulia Cerino
- Ospedale Guglielmo Da Saliceto – Piacenza: Chiara Citterio, Camilla Di Nunzio.
- ASST di Cremona: Annalisa Mancini.
- Policlinico Universitario A.Gemelli – Roma: Silvia Lamonica.
- Ospedale Sacro Cuore Don Calabria - Negrar (Verona): Silvia Resimini.
- Ospedale Sant' Andrea - La Spezia: Giovanni Sarteschi.
- Ospedale Di Belluno: Chiara Pavei.
- AOU di Ferrara – Ferrara: Nicholas Battistini.
- Ospedale Generale Provinciale – Saronno: Erika Gazzola.
- ASST di Cremona – Cremona: Annalisa Mancini.
- PO Jazzolino - Vibo Valentia: Marco Miceli.
- ASST di Lecco – Lecco: Silvia Pontiggia.
- ASST di Bergamo Ovest - Bergamo-Treviglio: Veronica Lonati.
- Ospedale Regionale Miulli, Covid Hospital, Acquaviva Delle Fonti – Bari: Giusy Giannandrea.
- Ospedale Maggiore – Modica: Claudio Sortino.
- AOUI di Verona - Borgo Roma – Verona: Serena Ravani.
- Ospedale Delmati – Sant'Angelo Lodigiano: Cristiano Uggeri.
- Ospedale Regionale Umberto Parini – Aosta: Genny Jocollé, Cristina Baré.

TOCIVID-19 Research Nurses

- IRCCS Policlinico San Donato – Milano: Irene Baroni, Daniele De Candia, Barbara Fiorini, Katiuscia Chierico, Francesca Romeo, Roberta Bottega, Laura Boccasile, Annamaria Corsaro.
- Azienda Ospedaliera San Salvatore – Pesaro: Claudia Spadoni.
- Ospedale Bassini - Cinisello Balsamo: Ria E Dipartimento Medico Ospedali Di Sesto San Giovanni E Cinisello Balsamo.
- ASST Spedali Civili Di Brescia: Silvia Chiari.
- Azienda Ospedaliera S. G. Moscati – Avellino: Giovanna Ercolino.
- Ospedale F. Spaziani – Frosinone: Vanessa Dell'uomo, Sabrina Viri.
- Ospedale Ca' Foncello – Treviso: Milena Minato, Lisa Gazzola, Balan Dorina.
- Ospedale Generale Provinciale – Saronno: Davide Gianelli.
- ASST Franciacorta - Presidio Ospedaliero di Chiari: Sonia Maspero.
- ASST della Valle Olona - Busto Arsizio: Maddalena Farinazzo.
- INMI L. Spallanzani, IRCCS – Roma: Paola Zanini, Antonella Sangiovanni.

TOCIVID-19 Pharmacists

- Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli - Clinical Trials Unit: Antonia Del Giudice.
- IRCCS Policlinico San Donato – Milano: Maria Margherita Dragonetti, Susanna Bordignon.
- ASST di Cremona – Cremona: Andrea Marco Machiavelli, Giulia Chiodelli, Annalisa Mancini.
- AORN Dei Colli – Napoli: Micaela Spatarella.
- Ospedale Bassini - Cinisello Balsamo: Davide Zenoni, Flavio Niccolò Beretta.
- Ospedale Bellaria – Bologna: Giuseppina Santilli.
- PO Sant'Elia – Caltanissetta: Rita Badagliacca.
- AOU Careggi – Firenze: Manuela Angileri.
- Azienda Ospedaliera S.G. Moscati – Avellino: Luciana Giannelli.
- Ospedale Di Trento – Trento: Annalisa Campomori.
- Ospedale Magalini - Villafranca di Verona: Patrizia Maimone.
- Ospedale Regionale Umberto Parini – Aosta: Andrea Fadda.
- Ospedali Riuniti Padova Sud - Padova: Sonia Faoro.

Other TOCIVID-19 Investigators (centres enrolling patients after March 24, 2020 only)

- Nuovo Ospedale Garibaldi Nesima – Catania: Bruno Cacopardo, Andrea Marino, Alessio Pampaloni, Benedetto Maurizio Celesia.
- AOU – Foggia: Gilda Cinnella, Daniela Labella, Rosa Roberta Caporusso.
- Ospedale Magalini - Villafranca Di Verona; Maria Danzi, Marta Fiscon, Marina Malena, Doris Fendt, Stefano Nardi.
- AO SS. Antonio e Biagio Cesare e Arrigo: Paolo Stobbione, Maria Laura Savi.
- ASST Melegnano e della Martesana: Andrea De Monte, Alberto Scala, Nicola Lucio Liberato.
- Ospedale Apuane – Massa: Dr. Sauro Luchi; Sauro Luchi, Antonella Vincenti.
- AO Ospedale di Circolo e Fondazione Macchi –Varese: Luca Cabrini.
- AOU di Modena: Giovanni Pinelli.
- AOU di Modena: Lucio Brugioni
- Ospedale Brindisi Senatore. A. Perrino – Brindisi: Domenico Potenza.
- Ospedale S. Maria delle Grazie di Pozzuoli – Napoli: Fabio Giuliano Numis, Giovanni Porta, Maria D'amico, Bianca Iengo.
- AOU Consorziale Policlinico Bari: Gioacchino Angarano, Annalisa Saracino.
- ARNAS Ospedale Civico di Cristina Benfratelli – Palermo: Livio Blasi.
- Ospedale San Giuliano – Giugliano in Campania: Pasquale De Negri.
- Ospedale Di Fermo – Fermo: Stefano Angelici, Antonella Farina, Giuseppe Pio Martino, Giuseppina Bitti.
- Ospedale Bolognini – Seriate: Alberto Tedeschi, Simona De Ponti.
- Ospedale Civile Spirito Santo - Pesacara: Adriana Agostinone, Giustino Parruti, Augusta Consorte, Antonella Frattari.
- AO San Giovanni di Dio e Ruggi d'Aragona- Salerno: Amelia Filippelli, Pasquale Pagliano, Alfonso Masullo, Carmine Sellitto.
- Ospedale Maggiore Carlo Alberto Pizzardi – Bologna: Massimo Reta, Nicolò Rossi, Luigi Raumer.
- Ospedale S. Maria Della Misericordia – Urbino: Silvia Andreassi, Paolo Brancaleoni.
- Ospedale San Francesco – Nuoro: Antonina Carai, Anna Maria Salerno.
- Ospedale Civile S. Salvatore – L'Aquila: Franco Marinangeli, Roberta Mariani, Antonello Ciccone.
- Ospedale Morelli - Sondalo: Carlo Meschini, Gianluca Santoboni, Claudio Angrisani, David Micarelli, Giovanna Tarquini, Vittorio Fregoni.
- AOU Di Ferrara: Carlo Alberto Volta.
- Ospedale INRCA – Ancona: Antonio Cherubini, Maria Simona Del Prete, Erika Ciarrochi.
- Ospedale Di Montebelluna: Francesca Tasca, Andrea Ballarin, Andrea Bianchin.
- Ospedale A. Cardarelli – Campobasso: Romeo Flocco,Vincenzo Cuzzone.
- Azienda Ospedaliera Umberto I –Siracusa: Maurilio Carpinteri.
- Ospedale Di Belcolle - Viterbo: Carlo Meschini, Gianluca Santoboni, Claudio Angrisani, David Micarelli, Giovanna Tarquini.
- Istituto Clinico Beato Matteo Pietro – Vigevano: Pietro Gallotti.
- Presidio Ospedaliero Ospedale Del Mare - Napoli: Federica Torre, Pio Zannetti.
- AO S.M.A. Sede Di Pordenone: Massimo Crapis, Sergio Venturini
- AO Santa Maria Nuova – Firenze: Massimo Barattini, Gianluca Gori.
- PO Annunziata –Cosenza: Antonio Mastroianni.
- Azienda Ospedaliera Regionale S. Carlo – Potenza: Giulio De Stefano, Michele Gilio.
- Ospedale S. Camillo De Lellis - Rieti: Giuseppe Rapisarda, Leonardo Gulisano, Maria Luisa Granata, Sebastiana Saglimbene, Maria Teresa Montalto, Ilaria Grasso, Silvana De Luca, Gaetano Magro, Florinda Messina.
- Ospedale Civile Di Ivrea: Bruno Scapino, Paolo Abrate, Chiara Francisco.
- Ospedale S. Luca - Vallo della Lucania: Laura Pesce.
- PO S. Marta e S.Venera – Acireale: Giuseppe Rapisarda.
- Ospedale Martini – Torino: Mauro Navarra.
- ASST di Vimercate: Michele Agosti, Silvia Pagani, Martina Piluso, Aristodemo Ricioppo.
- Ospedale Per Acuti Mater Salutis - Legnano: Silvia Tognella, Pierangelo Rovere, Marcello Vincenzi, Leonardo Ghirardi.
- ASST di Cremona: Daniele Generali.
- PO Mauro Scarlato –Scafati: Marco Ingrosso, Emilia Desiderio, Raffaele Molaro, Silvio Vitiello.
- Ospedale Maggiore – Chieri: Alessandro Mastroianni, Luca Lancione, Tonia Celeste Paone, Alessandro Meli, Stefano Mainardi, Valentina Rastellino, Antonia Ursillo, Paola di Grigoli, Elena Bovetto, Ivana Marina Stefanetto, Francesca Mazzola.

- Ospedale Ss Antonio E Margherita - Covid Hospital – Tortona: Antonio Daniele, Claudia Bisio, Pietro Delnero, Giovanni Morando, Antonella Nava, Lemut Francesco.
- PO Gorizia e Monfalcone - Gorizia: Fabio Fiammengo, Monica Regis.
- Ospedale San Giovanni Bosco – Torino: Dario Roccatello.
- Ospedale Sen. A. Perrino – Brindisi: Eugenio Sabato.
- Ospedale Civico – Chivasso: Marco Maria Liccardi, Cristina Bretto, Lorenzo Lutri, Enzo Castenetto
- Presidi Ospedalieri Riuniti ASL.6 Ciriè – Torino: Giuseppe Roberti, Maria Francesca Guidi
- ASST Rhodense – Rho: Francesco Bini.
- Ospedale Sandro Pertini – Roma: Maria Crisitna Zappa, Tiziana Trequattrini, Rosario Rivitti, Rossana Vigliarolo, Angela Succu, Marianna Lilli, Mattia Serao, Giuseppina Giogré, Annamaria Ruggieri, Kristoffer Flores, Giuseppe Vairo, Roberto Satira.
- Ospedale degli Infermi – Biella: Anna Lingua.
- Ospedale San Giuseppe – Empoli: Rosario Spina.
- Istituto Nazionale Malattie Infettive INMI L. Spallanzani IRCCS – Roma: Emanuele Nicastri, Gaetano Maffongelli, Filippo Barreca.
- AOU Senese –Siena: Sabino Scollet, Federico Franchi, Camilla Fabbri.
- Ospedale Policlinico – Verona: Pietro Minuz, Andrea Dalbeni.
- AOU Integrata – Verona: Paolo Zanatta, Domenico Gelormini.
- Presidio Ospedaliero V. Buzzi – Milano: Anna Mandelli, Feliciano Galderisi, Elena Zoia.
- Ospedale di Schiavonia: Maria Rita Marchi, Naile De Almeida Neves.
- Presidio Sanitario Gradenigo: Giorgio Carbone.
- PO Boscotrecase: Emilio Di Caterino, Anna Petrone.
- Ospedale S.S. Annunziata – Sassari: Carlo Andrea Usai, Francesco Bandiera.
- Ospedale Civile Di San Candido: Roberto Monti, Alex Hofer.
- AOU Policlinico Vittorio Emanuele – Catania: Giacomo Castiglione.
- Ospedale Mazzini –Teramo: Chiara Angeletti.
- Ospedale Ca' Granda Niguarda – Milano: Paolo Tarsia
- Ospedale Maggiore – Chieri: Lorenzo Veronese, Paola Daniela Artoni.
- Ospedale San Pietro Fatebenefratelli – Roma: Dora Larussa.
- AO Ospedale Niguarda Ca Granda – Milano: Roberto Fumagalli, Paolo Brioschi.
- Ospedale Santa Croce – Moncalieri: Alessandro Cerutti, Paola Pasquino, Fiore Gilberto.
- Presidio Ospedaliero Aziendale – Fidenza: Luca Cantadori.
- ASST Spedali Civili – Brescia: Gabriele Tomasoni, Lina Rachele Tomasoni.
- Azienda Universitaria Policlinico – Napoli: Nicola Coppola.
- Ospedale di Borgo San Lorenzo: Stefano Spolveri, Costanza Pollastri, Lorenzo Fico
- Madonna Del Soccorso - S. Benedetto:Tiziana Principi, Silvia Pierantozzi.
- AO S.Giovanni/Addolorata – Roma: Col. Costantino Fontana
- PO S. Francesco d'Assisi - Oliveto Citra: Giuseppe Lubrano.
- Presidio Ospedaliero Alto Tevere – Città di Castello: Laura Martinelli, Stefano Bravi
- AOU di Padova – Padova: Paolo Navalesi, Eugenio Serra.
- ASST Franciacorta: Paolo Gnesin, Enrico Cogi.
- PO S. Maria Della Pietà – Nola: Andrea Manzi, Ermenegildo Furino.
- Presidio Ospedaliero Di Chiari: Nicola Dasseni, Claudio Gentilini.
- Ospedale B. Ramazzini – Carpi: Elisa Benatti, Andrea Pignatti.
- Ospedale Civico - Partinico: Giuseppe Aiello, Mario Milia.
- AO Villa Scassi – Genova Sampierdarena: Maria Grazia Covesnon, Annalisa Brianti, Claudio Francesco.
- Ospedale Di Mondovì CN1- Cuneo: Blangetti Ilaria.
- Ospedale Civico – Chivasso: Fiammetta Pagnozzi, Sabrina Mietta.
- Ospedale Pesenti Fenaroli - Alzano: Alberto Rossi
- Ospedale S. Antonio Abate – Gallarate: Lorenzo Maroni, Vittorio Borroni, Claudio Bellintani.
- Ospedale AULSS 15 Alta Padovana: Camilla Sgarabotto, Giada Bizzotto.
- AO.Sant Anna E San Sebastiano – Caserta: Lucio Bucci.
- AO Loreto Mare – Napoli: Giovanni Spagnuolo.
- Ospedale Di Montebelluna: Moreno Agostini, Federico Carlo Caria, Filippo Testa.
- IRCCS AOU S. Martino – Genova: Raffaele De Palma, Giuseppe Murdaca.
- Presidio Ospedaliero di Chiari: Gabriele Zanolini, Nadia Sala.
- Ospedale Del Delta – Lagosanto: Erminio Righini.
- IRCCS AOU S. Martino – Genova: Roberto Pontremoli.

- Ospedale Moriggia Pelascini – Gravedona: Gianmarco Aondio.
- AORN A. Cardarelli – Napoli: Ferdinando Riccardi; Ferdinando Riccardi, Maria Giovanna De Cristoforo, Fausto De Michele.
- Azienda Ospedaliera S. G. Moscati - Avellino: Angelo Storti, Luciana Giannelli.
- PO SS. Trinità – Cagliari: Roberto Perra, Silvia Deidda.
- Azienda Ospedaliera Villa Scassi – Genova Sampierdarena: Caviglia Enrica, Federico Valastro
- ASST di Cremona: Matteo Giorgi Pierfranceschi, Fabio De Gennaro, Anna Laura Nardecchia, Alfredo Molteni.
- ASST di Cremona; Mariateresa Castellini.
- Ospedale San Pellegrino – Castiglione: Giovanni Buetto.
- Casa Di Cura Policlinico – Monza: Giovanbattista Ippoliti.
- Presidio Ospedaliero Di Arco: Domenico Sicheri.
- Presidio Ospedaliero Oglio Po – Casalmaggiore: Maria Grazia Bottoli.
- Ospedale di Vittorio Veneto: Blanca Martinez Lopez De Arroyabe, Alessandra Versaci.
- Casa Di Cura Villa Pini Sanatrix – Civitanova Marche: Giada Pallotti.
- Ospedale Civile E. Agnelli - Pinerolo: Marina Civita, Michele Grio, Nicola Liuzzi, Paola Molino, Mauro Pastorelli, Alberto Ricchiardi, Ferdinando Varbella, Angela Daniela Zeme.
- Ospedale Madre Giuseppina Vannini – Roma: Cinzia Sighieri, Grazia Portale.
- Casa Di Cura Villa Gemma - Gardone Riviera: Alessandro Olivetti, Carlo Pagnoni, Greta Moschini, Sabrina Boni, Alberto Guerra, Roberta Scudellari, Sabrina Vella.
- Presidio Ospedaliero Di Borgo Valsugana: Sandro Inchiostro.
- PO S. Maria dell'Olmo – Cava de Tirreni: Ornella Piazza.
- IRCCS Multimedica – Milano: Salvatore Guarino, Giorgio Aldegheri.
- PO Paolo Borsellino – Marsala: Giovanna Napoli.
- AOU Careggi – Firenze: Alessandro Morettini, Eleonora Caldini, Lorenzo Menicacci.
- AOU Careggi – Firenze: Filippo Pieralli, Monica Torrini.
- AOU – Careggi – Firenze: Loredana Poggesi.
- Clinica Pinna Pintor Srl – Torino: Enrico Maria Visetti.
- Policlinico di Alessandria: Enrico Maria Visetti.
- Presidio Ospedaliero Riuniti – Reggio Calabria: Carmelo Mangano.
- Casa Di Cura Villa Barbarano - Salo: Stefano Visconti.
- ASST di Bergamo Est: Pasquale Maietta.
- Ospedale SS. Capitanio e Gerosa – Lovere: Elisa Banfi, Stefania Cartella.
- Ospedale F. Spaziani – Frosinone: Bruna Venturi, Antonia Nuceri.
- Ospedale San Pellegrino - Castiglione: Elena Chiesa, Enrico Pacentra.
- Ospedale San Pellegrino - Castiglione: Gianluigi Panzolato.
- AO Villa Scassi – Genova Sampierdarena: Michella Giannotti, Cristina Bianchi.
- AOU di Modena: Antonello Pietrangelo.
- AOU Careggi – Firenze: Ombretta Para, Maria Serena Rutili.
- Presidio Sanitario Ospedale Cottolengo - Torino: Roberto Russo, Maurizio Lanfranco, Elisa Scalabrino.
- AOU Sant'Andrea – Roma: Agostino Tafuri.

- **Other TOCIVID-19 Study Coordinators (centres enrolling patients after March 24, 2020 only)**
- Ospedale degli Infermi – Biella: Elisa Perfetti.
- AO Villa Scassi – Genova Sampierdarena: Tosca Chiarello, Cristina Bianchi.
- Ospedale Di Montebelluna: Luca Cancanelli.
- AORN A.Cardarelli – Napoli: Manuela Otero.
- Casa Di Cura Villa Gemma - Gardone Riviera: Sabrina Vella, Greta Pannella, Francesco Bellucci.
- Presidio Sanitario Ospedale Cottolengo – Torino: Giovanna Ferrero.
- AOU Sant'Andrea – Roma: Carmen Vico.
- Ospedale Civile Spirito Santo - Pesacara: Maria Serafina Stillante.

Other TOCIVID-19 Research Nurses (centres enrolling patients after March 24, 2020 only)

- Ospedale A.Cardarelli – Campobasso: Giovanna D'Andrea.
- Ospedale S.Camillo De Lellis Rieti: Filippo Amoroso, Antonio Arcidiacono, Anna Maria Bella, Agata Belsito, Ylenia Berté, Giulia Carubia, Maria Grazia Caruso, Orazio Casella, Francesco Chiereleson, Chiara Costa, Daniela De Franco, Giuseppe Germanà, Antonio Messina, Diana Musumeci, Concetta Noto, Marco Valenti.

- PO Mauro Scarlato - Scafati: Carlo Sorrentino, Rosanna Panico, Giuseppe Schettino, Jolanda Piccoli, Antonio Pepe, Francesco De Rosa, Mario Ottaviano, Gerarda Marrazzo.
- Ospedale Sandro Pertini – Roma: Gianna Raponi, Stefania Diberardino.
- AOU Careggi – Firenze: Simona Bausi.
- Presidio Sanitario Ospedale Cottolengo – Torino: Alessandro Ferrari.

Other TOCIVID-19 Pharmacists (centres enrolling patients after March 24, 2020 only)

- Ospedale SS Antonio E Margherita, Covid Hospital – Tortona: Sara Francesca Marini.
- Presidio Sanitario Gradenigo: Elena Giubellino, Giorgio Innocenti.
- AORN A. Cardarelli – Napoli: Gaspare Gugliemi.
- Ospedale di Vittorio Veneto: Daniela Maccari, Izabela Baciu.
- Ospedale Maggiore – Chieri: Tonia Celeste Paone.